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Abstract 
Designer nucleases have greatly simplified small genome modifications in many 
genomes. They can precisely target a specific DNA sequence within a genome and 
make a double stranded break (DSB). DNA repair mechanisms of the DSB lead to 
gene mutations or gene modification by homologous directed repair (HDR) if a repair 
template is exogenously supplied. Thus, small, site directed mutations are easily and 
quickly achieved. However, strategies that utilize designer nucleases for more 
complex tasks are emerging and require optimization. 
 
To optimize CRISPR/Cas9 assisted targeting, an HPRT rescue assay was utilized to 
measure the relationship between targeting frequency and homology arm length in 
targeting constructs in mouse embryonic stem cells. The results show that different 
gene engineering exercises had different homology requirements. Targeted correction 
of a 4 bp mutation and insertion of 672 bp DNA improved steeply with homology 
arms up to 2 kb and 4 kb total homology, respectively, and had further increases with 
even longer homology arms. Deletion of a 1.5 kb stretch of DNA required homology 
arms of up 10 kb and supercoiled, circular DNA repair templates consistently had 
better targeting efficiencies than linearized templates.  
 
The repair efficiency of oligonucleotides (ODN) was determined to be inefficient, 
unless high concentrations of ODNs were supplied. ODNs were only able to repair a 
small 4 bp mutation, correction of a larger 15 bp mutation and deletion of a 1.5 kb 
stretch of DNA were not possible. HDR was found to be more efficient than non-
homologous end joining mediated ligation of DNA, and co-cutting of the genomic 
target and the donor was more efficient than insertion of a pre-linearized stretch of 
DNA. These results led to the conclusion that circular HDR vectors with long 
homology arms provide the greatest chance of achieving a complex gene engineering 
exercise.  
 
The optimized conditions found in this work were then utilized to complete a complex 
targeting exercise: humanization of the mouse Scn10a gene with a hybrid 
mouse/human BAC targeting construct. These results show how designer nuclease-
assisted targeting, along with optimized construct design, permits execution of 
previously impossible gene engineering exercises in mammalian genomes. 
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1. Introduction: 
1.1 Gene targeting and designer nucleases 
In 2007, the Nobel Prize in Medicine was awarded to Mario Capecci, Martin Evans 
and Oliver Smithies for their work in gene-specific modification in embryonic stem 
cells that led to knock out mice. Mouse embryonic stem cells (mESC) can be 
engineered via homologous recombination with engineered exogenous 
deoxyribonucleic acid (DNA). Targeted mESC are then used to make transgenic 
mouse models. Mice are frequently used in experiments as they are the laboratory 
animal most closely related to humans for which gene targeting can be easily applied. 
As of 2016, 16,883 of the ~20,000 transcribed genes of the mouse genome have been 
knocked out. This enormous feat was accomplished by a consortium of scientists 
across the globe(1) and gives an invaluable resource for scientists interested in gene 
function studies. While extensive progress has been made using gene targeting 
strategies, this technology is still limited by the low frequency of homologous 
recombination, and long, laborious selection and screening strategies.(2)   
 
So called “designer nucleases” are a valuable new tool in the toolbox for genome 
engineering. They induce a strand break (DSB) in the target locus and can either 
knock out genes through non homologous end joining (NHEJ), or increase gene 
targeting efficiency when a targeting construct is simultaneously provided through 
activation of the homologous repair machinery (HDR).(3,4) Over the last decade, the 
field of genetic engineering has seen technology advance from zinc finger nucleases, 
to transcription activator-like effector nucleases (TALENs), and finally Clustered 
Regularly Interspaced Short Palindromic Repeats/ CRISPR associated protein 9 
(CRISPR/Cas9) and Cfp1. However, the use of nuclease-assisted targeting to achieve 
complex precision genome engineering still remains challenging with many 
unresolved issues related to experimental design. 
 
Nuclease assisted targeting clearly has the potential to expand the area of genome 
engineering to encompass ambitious exercises. To exploit this potential for 
challenging genome engineering, such as the establishment of alleles for conditional 
mutagenesis, simultaneous biallelic targeting or large regional replacements, targeting 
constructs must be optimized. Several works have revealed that DSBs induced by 
INTRODUCTION 
2 
 
nucleases can be repaired by constructs with very short homology arms (HA) (5,6) or 
oligonucleotides (ODNs),(7,8) however, they do not look at optimal homology arm 
length for the different kinds of genome engineering exercises (large insertions, large 
deletions, repair of small lesions, etc) nor examine how the efficiency of targeting 
constructs compare to ODN repair or repair by blunt end ligation. Increasing targeting 
efficiency not only reduces workload and costs, it also opens up avenues for clinical 
applications and medical research.  
1.2 Scn10a 
Understanding pain disorders aids in disease diagnosis and helps patient treatment by 
revealing new drug targets. The human gene sodium voltage-gated channel alpha 
subunit 10 (SCN10A) encodes for the tetrodotoxin (TTX) resistant sodium channel 
Nav1.8 and is expressed primarily in small and medium diameter nocioceptive sensory 
neurons in the dorsal root ganglion.(9) SCN10A is involved in sensing pain from heat, 
cold, mechanical stimuli, neuropathic pain (chronic pain cause by nerve damage) and 
inflammation. It is a highly sought after target for pain treatment.  
 
Mutations within SCN10A can lead to several disease states, with a range of disease 
severity depending on the mutation. Variants of SCN10A have been indicated in Atrial 
Fibrillation,(10) (11) Long QT syndrome,(12) Brugada Syndrome,(13) and in 
inherited neuropathies.(14) Studies of SCN10A are important to understand the 
molecular mechanism of pain, and can help identify new targets for analgesic drug 
developments.(15,16)  
 
Commonly use anesthetics often block several Nav subtypes and can cause unwanted 
side effects. Selectively blocking Nav1.8, as it is almost exclusively expressed in 
nocioceptive neurons, would avoid those adverse effects while maintaining the 
desired anesthetic effects. Nav1.8 is also a possible target for heart arrhythmia 
therapies.(17) Six binding locations for natural toxins and synthetic derivatives have 
been identified, however, there are limitations to using animal models for human 
diseases. Studies of various disease states that are similar in mouse and human have 
served to highlight the differences between the species,(18) and illustrate that while 
mouse may be a model, it is not a perfect match for disease states. Therefore, in order 
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to better measure drug effects on Nav1.8, a model that uses the human SCN10A gene 
would be beneficial. 
 
The exon-intron structures of SCN10A are well conserved among human, rat and 
mouse.(19) The human SCN10A gene is 97 kb, has 27 coding exons and 1956 amino 
acids. The mouse Scn10a gene is 85 kb and has 27 coding exons and 1958 amino 
acids. All Navs have four homologous domains (D1-4) that consist of 6 
transmembrane -helical segments (S1-6) that are connected by intracellular loops 
(figure 1A). Both the N and C terminals are intracellular. S4 segments have positive 
amino acid residues that are predicted to be the voltage sensor.(20) Upon 
depolarization, the intracellular S4 segments move across the membrane to open the 
channel.(21) Elucidation of the crystal structures of Navs (22) (figure 1B) has led to 
the identification of the -helical binding sites of several natural and synthetic toxins 
that modulate sodium channels.(16)  
 
 
Figure 1 Nav1.8 structure Nav1.8 has four domains consisting of 6 transmembrane -helical segments 
connected by intracellular loops. Upon depolarization, the intracellular S4 segments move across the 
membrane to open the channel. Nav1.8 conducts Na+ ions through the pore and across the membrane 
during depolarization. (A) Depiction of the transmembrane segments of Nav1.8 (B) Side and top views 
of the Nav1.8 pore forming complex.(22) 
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1.3 Humanization of the mouse genome 
Inserting a human gene into the mouse genome, or “humanization,” is a useful 
technique in genome engineering for drug development and treatment. Randomly 
integrated small transgenes may function inefficiently due to missing cis acting 
elements(23) or be affected by the chromosomal landscape into which they are 
integrated.(24,25) Though large transgenes, such as BACs, can overcome some of the 
limitations of small transgenes, their large size makes it difficult to properly analyze 
copy number and to check for rearrangements.(26) 
 
Identifying and replacing the mouse ortholog in the mouse genome avoids some of the 
problems that transgenes face such as position effect or copy number. However, there 
are differences in how orthologous mouse and human genes are regulated,(27,28) and 
experimental design should take that into consideration. Additionally, the large size of 
some genes, such as SCN10A, which is 85 kb in mouse and 96 kb in human, still 
present problems with screening for rearrangements. Methods that insert large 
segments of DNA often use multiple targeting steps, which is undesirable as it can 
decrease germline transmission.(29-31)  
 
The use of designer nucleases to insert larger pieces of DNA presents a solution to the 
problem of targeting with large constructs. While targeting the mouse Mll gene with a 
64 kb targeting construct with selectable markers separated by 43 kb of DNA was 
achievable with low efficiency (6 %),(32) nucleases have been used to homozygously 
replace 2.7 kb of the THY1 gene at up to 11.6% of the targeted population or 
heterozygously at up to 14% of the population without selection.(33) The same report 
found similar results when replacing 9.8 kb of the BSG gene. Baker et al.(34) used 
CRISPR/Cas9 to humanize the Kmt2d gene, which involved a 42 kb regional 
exchange and homology arms as short as 4 and 7 kb, but increased targeting 
efficiency when using a construct with 4 and 50 kb homology arms.  
1.4 Designer nucleases 
Historically, targeted gene disruption, insertion, or replacement was achieved via 
homologous recombination. Homologous recombination, however, has a very low 
efficiency that limits its utility, which meant that complex designs were difficult to 
complete. The discovery that DSBs increase HDR or causes knock outs by NHEJ 
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increased the desire for efficient, specific, easy to use targeted nucleases. Designer 
nucleases reduce the positional effects that sometimes confound HDR, and increases 
HDR by several orders of magnitude. Over the past three decades, technology has 
been rapidly progressing in the field of designer nucleases from Zinc Finger 
Nucleases (ZFN), to TALENs, and finally CRISPR/Cas9. 
 
 
Figure 2 Designer Nucleases (A) Zinc finger nucleases consist of a pair 3-6 zinc finger (ZF) modules 
fused to a FokI nuclease. (B) TALENs consist of an N-terminal region containing the type II 
translocation signal, 15-20 repeat variable diresidue (RVDs) conferring DNA specificity, a nuclear 
localization signal (NLS) and a transcriptional activation domain fused to FokI. TALENs require a 5’ 
‘T’ and must dimerize to make a DSB (C) The gRNA-Cas9 complex binds to a target sequence next to 
a 3 nt ‘NGG” protospacer adjacent motif (PAM) where it generates a DSB 3bp upstream of the PAM.  
 
1.4.1 Zinc finger nucleases 
Zinc finger nucleases (ZFN) were the first gene editing strategy to use custom DNA 
endonucleases.(35) Zinc fingers are DNA binding transcription factors that are 
frequently found in eukaryotes. One zinc finger consists of about 30 amino acids in a 
 configuration.(36) The side chains of conserved Cys and His residues complex 
with a zinc ion. 
 
Amino acids on the surface of the -helix recognize 3-4 bp of DNA. Zinc fingers that 
identify all 64 of the possible nucleotide triplets have been developed, making a 
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modular system that is useful for custom design. Pre-selected modules can be 
tandemly linked together to target a specific DNA sequence. Non-natural arrays that 
contain more than three zinc finger domains allowed synthetic ZFN construction with 
higher specificity, which was promoted by the discovery of a highly conserved linker 
sequence.(37) This permits construction of zinc fingers that recognize 9-18 bp of 
DNA, which can confer very high specificity.(38)  
 
When a FokI cleavage domain is fused to the zinc finger DNA recognition module, a 
site directed nuclease is formed (figure 2A). FokI is a type IIS nuclease that makes 
cuts 9 and 13 nt downstream from the recognition site after dimerization.(39) FokI is 
only active upon dimerization, meaning two nuclease domains must be expressed to 
cause the DSB. The ZFN DNA target recognition site is two zinc finger binding sites 
(left and right) separated by 5-7 bp spacer that is cleaved by the FokI cleavage 
domain.  
 
One major hurdle to ZFN technology is the difficulty of producing ZFNs in the lab. 
The intellectual property of ZFN technology is owned by Sangamo Biosciences, who 
has arrangement to share reagents and methods with Sigma-Aldrich, who can then 
construct and validate a desired ZFN pair. This comes at a cost of several thousand 
euros. However, a ZFN can be designed for almost any stretch of DNA. Though the 
specificity of ZFNs is quite high, the efficiency remains relatively low, perhaps due to 
zinc finger module interactions and/or chromosomal landscape.  
1.4.2 TALs 
Transcription activator-like (TAL) effectors were first identified in the 
phytopathogenic bacteria Xanthomonas. The effector proteins are translocated to the 
cytoplasm of an infected plant cell via type III secretion system where they then 
modulate cell function by mimicking transcription factors.(40) 
 
TAL effectors consist of a N-terminal region which contains the type III translocation 
signal, a central domain of 34 amino acid (aa) tandem repeats, a nuclear localization 
signal, and a transcriptional activation domain(41) (figure 2B). The 34 aa repeats can 
be classified by their 12th and 13th amino acid residues, with each RVD recognizing a 
single nucleotide in the target DNA sequence.(42,43) Four repeats- HD, NG, NI, and 
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NN account for 75% of the total repeat usage, but over 20 repeats have been 
identified.(43) In naturally occurring TALs, the nucleotide ‘T’ is generally conserved 
at the 5’ end of the recognition sequence (position 0) and the last repeat only contains 
20aa and is considered a half repeat.(42,43) The protein sequence preceding the TAL 
RVD’s is somewhat similar to the RVD sequence, and forms a degenerate loop 
similar to that found in the RVDs that may loosely interact with the ‘T.’(40,44) 
However, work was done to evolve the N-terminal domain to allow for recognition of 
all the bases.(45) RVDs can range in number from 1.5 to 28.5(46) with the majority of 
naturally occurring TALs having between 12 and 27.(41) However Boch et al.(42) 
found that a minimum of 6.5 RVDs were required to induce gene expression, and 
RVDs with 10.5 or more repeats lead to stronger gene activation. 
 
Analysis of the crystal structure of TAL effectors indicates that each TAL repeat 
comprises of a left-handed, two helix bundle: a short -helix formed from positions 3-
11 and a second, bent -helix formed by positions 15-33.(44,47) The two helices are 
separated by a short RVD containing loop, which positions the RVDs close to the 
sense strand in the DNA major groove.(44,47) It appears that position 12 does not 
directly recognize DNA, but rather stabilizes the local conformation of the loop and 
aids position 13 to specifically recognize a DNA base.(47) The TAL repeat forms a 
right-handed, super-helical structure that tracks along the major groove of the DNA 
duplex, with the inner ridge of the super-helix having a positive electrostatic potential 
that allows interaction with the negatively charged phosphate of the DNA 
backbone.(44,47) 
1.4.2.1 TALENs 
TALs can be paired with a nuclease to cleave double stranded DNA at a specific site- 
thus introducing TALENs to the toolbox of genetic engineering. Following the design 
of zinc finger nucleases, a TALEN pair is designed to recognize a sequence that is 
separated by a spacer. The sequence specific recognition of TALs direct a FokI 
monomer to a sequence where the FokI dimerizes, cleaves and causes a double 
stranded break (DSB) within the spacer.(44)  
 
Several TALEN assembly kits are provided at a nominal charge by depositories, 
which mean that TALENs can be designed and assembled in about a week. These kits 
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come with more than 70 plasmid samples that need to be organized and stored. 
Assembly is a multi-step process that is relatively laborious and technically difficult. 
Once assembled, due to their repetitive nature, RVD order can only be checked by 
restriction digest. TALEN pairs are difficult to validate in vitro, but can be expressed 
and checked in vivo, often with a T7E1 or CelI nuclease assay. However, the 
efficiency of TALENs within the same work, even targeting the same locus varies 
from low to high, or even showing no activity.(48-51) This may be due to some 
undetermined property of TALEN design, or to the methylation status of the DNA 
target.(52,53) The ability to relatively easily design and assemble TALENs in the 
laboratory and reduced cytotoxicity (section 1.4.4) makes them more attractive that 
ZFNs, but their sensitivity to DNA methylation makes them difficult to use in 
cultured cells, which accumulate methylation marks with passaging.  
1.4.3 CRISPR/Cas9 
Bacteria have evolutionarily developed a defense mechanism against phage infection 
and plasmid transfer known as clustered regularly interspaced short palindromic 
repeats (CRISPR) and CRISPR associated protein 9 (Cas9).(54) This natural defense 
system has been adapted and repurposed as a RNA-guided DNA targeting genetic 
engineering tool.(55) (56) The Streptocococcus pyogenes (S. pyogenes) Cas9 nuclease 
recognizes a 20 bp DNA sequence via a single guide RNA (gRNA) (figure 2C). This 
results in nucleotide-nucleotide recognition, compared to the module-nucleotide 
recognition of TALENs and ZFNs and may give CRISPR/Cas9 a higher DNA 
recognition specificity.  
 
A short, conserved 3 bp motif (NGG for S. Pyogenes) must be located in close 
proximity to the 20 bp targeted recognition site. This is known as the protospacer 
adjacent motif, or PAM. When the Cas9-gRNA complex binds to its target DNA 
sequence next to a PAM, it generates a blunt ended DSB 3 bp upstream of the 
PAM.(57) (55) 
 
S. Pyogenes Cas9 is a 1,368 aa DNA endonuclease. The HNH-like nuclease domain 
cleaves the DNA strand complementary to the target. The RuvC-like nuclease domain 
cleaves the non-target strand.(58) Mutating H840A of the HNH or D10A of the RuvC 
domain generates a nickase, rather than a DSB.(55) Using paired nickases doubles the 
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recognition site, thus decreasing off target effects (section 1.4.4), and makes a DSB by 
making off set cuts. 
 
CRISPR/Cas9 is easily assembled in the lab, either as an expression plasmid (requires 
simple cloning) or produced in vitro and combined with Cas9 protein to form an RNP. 
In vitro production of the gRNA utilizes commercially available kits, and eliminates 
cloning, which makes it even more attractive. gRNA’s are easily designed and 
verified in vitro via Cas9 cleavage assays, and in vivo with T7E1 or CelI cleavage 
assays. Though poorly designed gRNAs can lead to off target effects (section 1.4.4), 
well designed gRNAs have few off target effects, and though different gRNA’s have 
different cleavage efficiencies,(8,33,59) most gRNAs exhibit measurable cleavage. 
1.4.4 Designer nuclease specificity and off target effects 
While designer nucleases efficiently cleave target DNA, they can also make unwanted 
cuts at genomic sites that have a high sequence similarity to the target location. In the 
extreme, these off target effects can cause cell toxicity, as uncontrolled DSBs can 
cause chromosomal rearrangements and nonsense mutations. Less drastic off target 
effects can cause SNPs or unintended integration of foreign DNA into the genome. 
Each of the three designer nuclease classes have reported off target cleavages, and 
have reports to reduce these effects (reviewed in(60)). 
 
As FokI nucleases must dimerize to cleave DNA(61), the larger DNA recognition site 
of the pair contributes to high specificity. ZFN pairs usually recognize 18-36 bp 
target, and a TALEN pair recognizes a 30-40 bp target, which surpasses the 
complexity of the genome, meaning that well designed sites will have a single 
recognition site genome wide. In silico identification of unique target sites, however, 
does not translate to perfect target recognition in vivo. CRISPR/Cas9, in contrast, 
functions as a monomer, which may contribute to non-specific cleavage, especially in 
poorly designed recognition sequences. Conversely, however, RVD and ZF 
degeneracy may contribute to alternative nucleotide recognition while the nucleotide-
nucleotide recognition of CRISPR/Cas9 may be less tolerant of mismatches. 
 
ZFNs prefer guanine rich targets, which reduces the number of sequences they can 
target.  Commercially produced ZFNs can be screened for cleavage efficiency, but 
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come at a higher cost. ZFNs constructed from publicly available ZF resources are 
often cytotoxic, which may be a result of their off target effects.(62)  
 
TALENS are generally not cytotoxic, but can still produce off target mutations.(63) 
There are several web-based resources that screen the target genome for potential of 
target locations (for common genomes such as mouse, rat or human). Kim et al. has 
shown that off target effects of TALENs can be prevented as long as the target 
sequence is at least 7 nucleotides different from any other genomic site.(64) 
 
Cas9 requires a PAM, which for S. pyogenes is 5’-NGG-3’, however it can cleave 
sites with a 5’-NAG-3’ or a 5’-NGA-3’, though it loses some efficiency.(65) 
CRISPR/Cas9 can also tolerate some mismatches in the PAM distal sequence, though 
mismatches in the seed region are not as well tolerated. Finally, CRISPR/Cas9 can 
cleave off target sites with several additional or missing nucleotides, making 
thousands of possible off target sites in the genome.(66) 
 
Most publications test only for mutations at predicted off target sites, and Sanger 
sequencing of DNA from individual clones is the gold standard of confirming the 
presence or absence of off target effects. However, this method is expensive and time 
consuming to screening many clones. Interestingly, whole genome/exome sequencing 
of clonal populations of human cells that were modified with ZFNs,(67) TALENS and 
CRISPR/Cas9(68) reveal that mutations are almost absent in the entire genome of an 
individual clone, though off target mutations are detectible in a bulk population of 
cells. This is because the mutation frequency of on-target sites is orders of magnitude 
higher than mutations at off-target sites.  
 
Nonetheless, it is important to understand off target effects, and try to prevent them. 
Indeed, there are several ways to decrease off target effects in designer nucleases. The 
easiest and most efficient way to reduce off-target effects is a well-designed 
recognition sequence. There are several free programs that predict off target sites, and 
utilizing only highly rated recognition sequence reduces the chances of off target 
sequence recognition. The use of paired nickases in Cas9 (thus requiring two nickases 
each cleaving a single strand to form a double strand break) decreases the rate of 
HDR, but decreases off target effects.(57,69) Cas9 ribonucleoprotein complexes 
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rapidly cleaves target sites, and are rapidly degraded by endogenous proteases, thus 
reducing off target effects, without compromising on target mutation 
frequencies.(70,71) The final way to reduce Cas9 off target effects is to carefully 
control the amount of Cas9 and gRNA delivered, as high levels of Cas9 leads to off 
target effects.(65,72,73) 
1.5 DSB repair pathways 
Genome integrity is important for cell survival and proliferation. Different types of 
DNA lesions stall replication fork progression and can lead to replication fork 
collapse and therefore DSB formation. The cell has four different mechanisms to 
repair DSBs: classical-NHEJ (C-NHEJ), alternative NHEJ (alt-EJ), single strand 
annealing (SSA) and homologous recombination (HR) (figure 3). Which pathway the 
cell chooses depends on several interrelated factors, including cell cycle and end 
resectioning. End resection is diminished in non-cycling cells, and therefore NHEJ is 
favored over pathways that require resection.(74)  
 
 
Figure 3 DSB Repair Pathways The four mechanisms to repair DSB are depicted: C-NHEJ, alt-EJ, 
SSA and HR. C-NHEJ results in quickly repaired DSB via ligation, and typically results in 0-4 nt loss. 
Alternative-NHEJ (Alt-EJ), SSA, and HR all occur after end resectioning. Alt-NHEJ uses small 
homologies to repair DSBs, resulting in the loss of up to 20 nt. SSA occurs after extensive end 
resectioning and is the result of end joining between genomic nucleotide repeats via reannealing of 
ssDNA covered by RPA and RAD52, resulting in the loss of large stretches of DNA. HR uses a 
homologous DNA for repair, and requires strand invasion mediated by RAD51 and is typically error 
free. 
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In C-NHEJ the ends are not resectioned and the DSB is repaired via blunt end 
ligation, independent of sequence homology. C-NHEJ has fast kinetics, and protects 
the genome by suppressing chromosomal translocations.(75) The C-NHEJ pathway 
utilizes many factors, such as Ku70/80, DNA-PKCs, and DNA ligase IV.  
 
Once C-NHEJ is ruled out by end resectioning, a competition is held between the 
three remaining pathways. End resectioning generates 3’ single-stranded DNA 
overhangs. The cell decision to resect ends likely directs the choice of pathway and 
repair outcome.(74) Alt-EJ, SSA, or HR can repair the resected junction. The end 
resection begins with ‘end clipping’ by the MRE11 nuclease and CtlP, and relatively 
few base pairs (ie up to 20 bp in mammalian cells) are removed, thus producing a 
small overhang that can be repaired by alt-EJ, which uses microhomology pairing for 
the repair. The evidence of the alternative end joining pathway has been presented in 
recent years, as cells deficient in C-NHEJ could still repair DSBs by end joining.(76)  
 
‘Extensive resection’ is the second phase of end resectioning and involves helicases 
and exonucleases (like BLM, CtlP, EXO1 and WRN) producing long stretches of 
ssDNA. Once the long stretches of ssDNA are produced, the cell is committed to HR 
or SSA.(74,77) RAD51 and RPA compete to bind to the ssDNA to prevent secondary 
structure formation, DNA end degradation, and prevent spontaneous annealing 
between microhomologies(78) (thus regulating alt-EJ).(79)  
 
HR uses a sister chromatid or homologous DNA for repair, and requires strand 
invasion mediated by RAD51, and is typically error free. Once the ends are resected, a 
D-loop is formed after homology search and strand invasion. In the following steps, 
RAD51 is removed from dsDNA, strand extension, junction resolution and chromatin 
reassembly occurs.(80) This is a complex process that is mediated by several 
checkpoints and many different factors. This naturally occurring cellular process is 
exploited during gene targeting. DNA can be inserted, deleted, or replaced when 
homologous stretches of DNA surrounding the change are supplied. 
 
SSA does not require a donor sequence and does not require strand invasion, and 
occurs independently from RAD51. Rather, SSA repairs via resected ends that anneal 
to exposed complementary sequences. SSA consists of end joining between genomic 
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nucleotide repeats via reannealing of ssDNA covered by RPA and RAD52. This 
ultimately results in a loss of DNA, as one copy of the repeat and the sequence 
between repeats are deleted in the repair product.(81) 
 
The cell cycle regulates the competition between C-NHEJ and end resectioning 
dependent pathways. C-NHEJ occurs mostly in G0/G1 and G2, but can occur 
throughout the cell cycle.(82,83) In G1, BRCA1 recruitment is inhibited and DNA 
end resection is blocked, thus promoting C-NHEJ. However, in S/G2, where DNA 
replication is highest, cyclin dependent kinases (such as ATM) phosphorylate 
substrates that favor the three resection depend pathways: HR, alt-EJ, or SSA.(83) 
 
Each of the four types of repair have typical outcomes for DSB repair.  This is 
especially important to recognize when using designer nucleases, as the DSBs they 
cause can lead to different outcomes. For instance, the FokI nuclease (used with ZFNs 
and TALENs) leave a 4 nt 5’ overhang. This means that end resectioning must occur, 
and HR, or one of the error prone end resection pathways must repair the lesion. Cas9, 
however, makes a straight DSB that can be repaired through blunt end ligation (C-
NHEJ) as it competes with the end resectioning pathways. Typically, C-NHEJ is 
either perfectly repaired through blunt end ligation, or results in small 1-4 nt deletions. 
HR results in either accurate repair, or loss of heterozygosity. SSA results in large 
deletions, and alt-EJ produces chromosomal rearrangements, and small insertions or 
deletions.(80) 
 
Synchronizing cell culture before introducing a designer nuclease can help direct 
repair to a certain pathway, as different pathways are chosen at different parts of the 
cell cycle.(83) Therefore, if one desires HDR, introduction of a repair template and 
nuclease and synchronization of the cell cycle to S/G2 will increase the chance of HR. 
Alternatively, if a knockout phenotype via small indels is desired, a nuclease that 
produces overhangs is beneficial. Finally, inhibiting or enhancing modulators of any 
of the pathways can sway the cell’s decision for or against that pathway.(84) 
1.6 Recombineering 
Recombineering is a method of in vivo DNA engineering that utilizes phage-derived 
recombination systems in E. coli and other bacteria. The first uses of phage derived 
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recombination systems utilized the lambda phage(85) and the RecE/RecT system of 
the Rac prophage.(86) The term “recombineering” comes from recombination-
mediated genetic engineering.(87,88) Plasmids, BACs and the E. coli genome have 
all been modified using recombineering, without the need for traditional in vitro 
cloning methods such as restriction digestions and ligation reactions that rely on the 
location and sequence of restriction endonucleases.(89) Recombineering is 
advantageous in that it overcomes the limitations of cloning, as it is independent of 
restriction sites. The location of the recombineering reaction is defined by the 
sequence of user defined homology arms that flank a recombineering cassette. A 
typical homology arm is 35-50 bp long, as this is enough to identify a unique locus in 
even the largest mammalian genome. Recombineering is based on constitutive or 
inducible expression of the red  genes of the Red system or the recET genes of the 
RecE/RecT system together with red  in E. coli.(90) Expression of the red  protein 
increases the stability of transformed linear DNA substrates by inhibiting the RecBCD 
nuclease. This means that the very long homology arms (of about 1000 bp) that was 
used in initial experiments(85) are unnecessary and that shorter homology arms, 
which can be introduced during PCR via chemically synthesized olignucleotides that 
contain both the ~50 bp homology arm and a ~21 bp PCR primer can be easily used 
for DNA engineering.(86) RecE and Redα are 5´->3´ exonucleases, and RecT and 
Redβ are DNA annealing proteins. DSB repair is initiated by RecE or Redα. First 
RecE or Redα degrades the DNA in a 5’-3’ direction, starting from the DSB, thereby 
creating a 3’ ssDNA overhang. Then, RecT or Redβ binds to the ssDNA forming a 
recombinogenic proteonucleic filament which is used in recombination, either by 
single strand annealing or by strand invasion.(91,92)  
 
Plasmid based recombineering expression systems have the advantage of being easily 
transferred into the desired E. coli strain. The recombineering genes are typically 
expressed in trans from a low to medium copy number, temperature-sensitive pSC101 
plasmid under the control of the L-arabinose inducible pBAD promoter.(93) This 
allows for temporal control of gene expression in the cell of choice by a plasmid that 
can be eliminated from the host by a temperature shift.  
 
INTRODUCTION 
15 
 
Recombineering can be used for many applications, among them: a) utilizing gap 
repair to subclone sections of DNA from larger DNA molecules (ex BAC),(94,95) b) 
insertion, deletion or replacement of a selectable fragment,(86,94) c) single-stranded 
oligonucleotides for site-directed mutagenesis (ssOR) for single point mutations and 
small insertions and deletions(96-98) d) high throughput pipelines for rapid 
generation of modified BACs based on sequential recombineering.(99-101) 
1.7 Gene targeting 
The use of recombineering greatly simplifies the design and assembly of the 
constructs that are required for gene targeting. There are many possibilities in the 
design of targeting vectors that can be used for a variety of purposes. For gene 
targeting without a nuclease, DNA must be linear, with long stretches of isogenic 
DNA (3-5 kb HA on each side), and require a strategy to detect targeting must 
(common strategies are Southern assay, long range PCR and loss of allele assays). 
Using selectable markers (such as drug resistance genes) enriches targeting events, 
and additional sequences, such as site-specific recombinases can be used to make 
knock out or conditional alleles. Recombineering easily allows vector assembly by 
sublcloning from bacterial artificial chromosomes (BAC) libraries, integrating 
cassettes, and integrating additional DNA sequences such as RE sites or site specific 
recombinase recognition sequences.  
 
mES cells provide an excellent and versatile model for the study of mammalian 
biology. mESC can be derived from early mouse embryos,(102,103) can be modified 
with exogenous DNA(104) and have the ability to reconstitute fertile animals from 
cultured cells, i.e., to colonize all of the tissues of the embryo, including the germ line. 
Mouse embryonic stem (ES) cells have a higher frequency of HDR than other 
cultured cells- most likely due to their rapid growth and resultantly high DNA 
replication, which means that S phase constitutes a greater proportion of the cell 
cycle. Though gene targeting is also possible in ES cells from other species such as 
human and rat;(105,106) the legal restrictions placed on human ESC manipulation, 
the high efficiency of mouse gene targeting, and the relative low cost of mouse 
maintenance mean that mouse is one of the most used mammalian models.  
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There are many different ways to engineer the mouse genome, and transgenic mice 
have opened the door for major advancements in biomedical research. A common 
application of gene targeting is the generation of knockout (KO) mice, in which a 
gene is disrupted resulting in a non-functional protein. If this “loss of function” causes 
a phenotypic change, this can be studied and the function of this gene and the protein 
it codes for can be identified. In addition to being used for animal studies, mES are a 
model for pluripotency and stem cell issues.(107) mESC can also be differentiated in 
to other cell types(108-111) which allows for the study of lineage commitment and 
differentiation.(112)  
1.8 Embryonic stem cells early mouse development 
Mammalian development begins after fertilization, with the single cell zygote. The 
zygote undergoes a series of cleavage divisions leading to the formation of the 
morula, which consists of cells called blastomeres. Further divisions and morphogenic 
changes result in the early blastocyst. The blastocyst consists of the inner cell mass 
(ICM) and the surrounding trophectoderm cells which forms the extra embryonic 
tissues. While the zygote and blastomeres are totipotent, the ICM consists of 
pluripotent cells that will form the embryo proper. In late blastocyst formation, the 
ICM forms a monolayer of primitive endoderm that encloses the remaining 
pluripotent epiblast cells and the embryo is ready to implant into the uterus. The next 
step is gastrulation, in which the epiblast specializes into the three germ layers 
(endoderm, ectoderm, and mesoderm) and the germ cell lineage.(113) Fetal somatic 
stem cells, which are multipotent, further differentiate into the cells of each organ as 
the fetus grows and develops. A small percentage of fetal stem cells remain 
multipotent after fetal development and form adult stem cell pools, which are required 
for homeostasis or regeneration. Most adult tissues maintain adult somatic stem cells, 
which divide asymmetrically giving rise to one stem cell and one committed 
progenitor. The progenitor can then differentiate into the specialized cells of the 
tissue. 
 
The ICM of the blastocyst can be extracted and cultured in vitro. In order to be 
classified as ES cells, they must meet several criteria: they must be undifferentiated 
and able to divide, they must be able to develop into the endoderm, ectoderm and 
mesoderm, and they must have the ability to self-renew. In culture, ES cells can be 
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maintained in an undifferentiated state when grown on mouse MEFs in medium 
containing serum.(102,103) ES cells can be weaned from MEF feeders and cultured in 
culture medium supplemented with LIF.(114) Serum can be replaced in growth 
medium by bone morphogenetic protein 4 (BMP4). Cells maintained with LIF and 
serum, however, vacillate between a naïve and “primed” state, and have mosaic 
transcription factor expression levels.(115) Supplementing culture media with two 
inhibitors (2i- PD0325901 and CHIR99021) inhibits Mitogen-activated protein kinase 
(MEK) and Glycogen syntase kinase 3 (GSK3)(116) and returns ES cells to their 
“ground state” of pluripotency.(117) 
 
Alternatively, adding growth factors to culture medium can promote ES cell 
differentiation into specific cell types.(107,118) This allows for the study of large, 
homogenous cell populations at different developmental stages. The molecular study 
of genes, the proteins they code for, and their interactions with other proteins, DNA, 
and RNA has been greatly advanced by the development of 
immunoprecipitation,(119) mass spectrometry(120) and chromatin 
immunoprecipitation (ChIP/ChIP Seq) and RNA profiling has greatly improved our 
understanding of what is occurring in cells at a molecular level both in the ES stage 
and upon differentiation. 
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2 AIM 
 
Nuclease assisted targeting has drastically changed the outlook of gene therapy over 
the last decade. Designer nucleases like CRISPR/Cas9 have greatly simplified small 
genome modifications in many genomes. DNA repair mechanisms of nuclease 
induced DSB leads to gene mutations or gene replace by homologous directed repair 
(HDR) if a repair template is exogenously supplied. Thus, small, site directed 
mutations are easily and quickly achieved. However, strategies that utilize designer 
nucleases for more complex tasks are emerging and require optimization. 
 
Several works have revealed that DSBs induced by nucleases can be repaired by 
constructs with very short arms(5,6) or even oligonucleotides (ODNs) (7,8), however, 
they do not look at optimal homology arm length for the different kinds of kinds of 
genome engineering exercises (large insertions, large deletions, repair of small 
lesions, etc) nor examine how the efficiency of targeting constructs with smaller arms 
compare to ODN repair or repair via NHEJ mediated ligation of microhomologies or 
blunt ends. Increasing targeting efficiency not only reduces workload and costs, it also 
opens up avenues for clinical applications and medical research. 
 
Therefore, in this work, I aim to clarify optimal construct design for designer nuclease 
assisted targeting by evaluating the targeting efficiency of different constructs. I will 
examine the impact of homology arm length on targeting efficiency in different gene 
engineering exercises and evaluate the requirements for long stretches of isogenic 
DNA in the homology arms when utilizing nuclease assisted targeting. I will compare 
the efficiency of HDR to repair techniques that utilize minimal or no homology such 
as ODN repair and NHEJ mediated ligation, and utilize this information to form a 
recommendation for optimal vector design for nuclease assisted targeting in 
mammalian genomes. I will then use these optimized vector design to attempt an 
ambitious targeting exercise: humanization of the mouse Scn10a gene. 
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3 Materials and Methods 
3.1 Instruments 
CASY cell counter (model TTC)  Roche 
CK 40 Olympus 
CKX 41 Olympus 
Electroporator 2510  Eppendorf 
G:Box gel documentation system  Syngene 
Genepulser Xcell Biorad 
Mx3000P / Mx3005P multiplex PCR instr.  Agilent 
NanoDrop ND-1000 spectrophotometer  PeQLab 
Nucleofector II device  Lonza 
Phosphoimaging plates BAS cassette 2340  Fujifilm 
Phosphoimaging scanner FLA 3000  Fujifilm 
Stereomicroscope with camera Nikon SMZ 1500 
Thermocycler ep Gradient S  Eppendorf 
Thermomixer compact  Eppendorf 
Ultrospec 2100 Pro Amersham Biosciences 
UV Stratalinker 2400 Stratagene 
Vortexer VortexGenie2  Scientific Industries 
Water bath 1003  GFL m.b.H. 
3.2 Consumables 
10 cm tissue culture dishes  Nunc  168381 
6 - and 24 - well plates  Nunc  
140675, 
142475 
96 - well plate (flat bottom)  Greiner Bio-One  4410193 
Blotting paper  
Bio-Rad 
laboratories  170-3967 
Cryo tube vials Nunc  366656 
Microlance needles (23G)  
Beckton 
Dickinson  300800 
Electroporation cuvettes (0.4 cm) VWR 732-1137 
Electroporation cuvettes (0.1 cm) VWR 732-2267 
Nylon Transfer Membrane: Biodyne B 0,45 μm 
PALL Life 
Sciences  60200 
Quick Spin G-50  Sigma 11273973001 
Maxi-500 Columns Qiagen 10063 
 
3.3 Chemicals/ Reagents 
Acetic Acid VWR  20104 
agarose Serva 11404 
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Ampicillin sodium salt Sigma A9518 
QC Wash Buffer Qiagen 1015371 
Bovine serum albumin (BSA) Sigma Aldrich  A7906 
Chloromphenical Sigma Aldrich 23275 
Coomassie Brilliant Blue G20 Merck Millipore  115.444.025 
Dimethylformamide (DMF)  Sigma Aldrich  D4551 
di-Sodium hydrogen phosphate dihydrate 
(Na2HPO4 * 2 H2O) Merck Millipore  106580 
Dithiothreitol (DTT)  Sigma Aldrich  D9779 
Ethanol VWR  20821 
Ethidium Bromide Sigma Aldrich  E8751 
Ethylenediaminetetraacetic acid (EDTA)  Merck Millipore  108418 
Formaldehyde Merck Millipore  104003 
Glutaraldehyde  Sigma Aldrich  G6257 
Glycerol  Merck Millipore  104092 
Hydrochloric acid  VWR 20252 
Hygromycin-B Roth 1287.2 
Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) Sigma N-1127 
Isopropanol  VWR  20842330 
L arabinose Sigma A3256 
Agar, Bacteriological Amresco 232-658-1 
Magnesium chloride (MgCl2)  Sigma Aldrich  208337 
Methanol VWR  20847 
Kanamycin sulfate  Sigma K1377 
N-Lauroyl sarcosine sodium salt  Sigma Aldrich  L9150 
ortho-Nitrophenyl-β-galactoside (ONPG) Roth CN22.1 
P1 Resuspension Buffer Qiagen 1014854 
P2 Lysis Buffer Qiagen 1014939 
P3 Neutralization Buffer Qiagen 1014955 
Phenylmethylsulonyl fluoride(PMSF) Sigma P-7626 
Potassium chloride (KCl)  Merck Millipore  529552 
Potassium dihydrogen phosphate 
(KH2PO4)  Merck Millipore  104873 
Potassium-ferricyanide (K-Ferricyanide) 
Sigma Aldrich  Sigma Aldrich  P8131 
Potassium-ferrocyanide (K-Ferrocyanide)  Sigma Aldrich  P9387 
QBT Equilibration Buffer Qiagen 1015291 
QF Elution Buffer Qiagen 1025572 
Sodium chloride (NaCl)  VWR  27810 
Trisodium Citrate dihydrate Merck Millipore  1.064.481.000 
Sodium dihydrogen phosphate (NaH2PO4 
* H2O)  Merck Millipore  1.063.461.000 
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Sodium dodecyl sulfate (SDS) (20% 
Solution) Fisher Scientific BP1311-1 
Sodium hydroxide (NaOH)  Merck Millipore  1.064.981.000 
TBE buffer (10x)  AppliChem  A0972 
Tetracyclin Hydrochloride Sigma T-3383 
Tris Carl Roth  AE15 
X-galactosidase (X-gal)  Fisher Scientific  10365410 
 
3.4 Cell Culture Chemicals/Reagents 
2-Mercaptoethanol (β-Mercaptoethanol) Sigma Aldrich  M6250 
6TG Sigma  A 4660 
Chicken serum  Invitrogen  16110082 
CT99021  ABCR  AB 253776 
D-glucose Merck Millipore  108342 
Dimethylsulfoxide (DMSO)  Sigma Aldrich  D2650 
DMEM + GlutaMAX  Invitrogen  61965-026 
Fetal calf serum (FCS)  PAA  A15-101 
Gelatin  Sigma Aldrich  G2500 
Geneticin (G418 sulfate)  Gibco/Invitrogen  11811-064 
HAT Invitrogen 21060‐ 017 
HEPES  Sigma Aldrich  54457 
L-glutamine  Invitrogen  25030-024 
LIF 
Obtained by cultivation of human 
embryonic kidney cells (293) 
Lipofectamine Ltx 
Lipofectamine LTX 
and Plus reagent  Invitrogen  
Mitomycin C  Sigma Aldrich M0503 
Non-essential amino acids (NEAA)  Invitrogen  11140-035 
PD0325901  ABCR  391210-10-9 
Penicillin/Streptomycin  Invitrogen  15140-122 
Sodium pyruvate  Invitrogen  11360-039 
Trypsin 2.5% (10x)  Invitrogen  15090-046 
 
3.5 Kits and Laders 
1 kb DNA ladder  NEB  N3232S 
100 bp DNA ladder  NEB  N3231 
Amaxa Mouse ES Cell Nucleofector Kit Lonza VPH 1001 
Deoxynucleotide mix (dNTPs)  NEB  N0447S 
High Prime Kit Roche 
11 585 592 
001 
Invisorb Spin DNA Extraction Kit Stratec 1020110300 
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Mega Shortscript T7 Ambion AM1354 
MSB Spin PCRapace Stratec 1020220400 
NEB Buffers NEB 
Provided with 
Enzyme 
Nucleobond Bac100 Macherey-nagel 740579 
Plasmid Safe DNAse Epicentre E3110K 
Voytas TALEN 
Gift from Voytas 
Lab  
 
3.6 Enzymes 
BsaBI NEB R0537S 
BsaI NEB R3535S 
BsmI NEB R0134S 
BssSI NEB R0680S 
Bstz171 NEB R3594S 
Cas9-NLS Wt protein P.E.P MPI-CBG  
EcoNI NEB R0521S 
EcoRI NEB R3101S 
Esp3.I Thermo Scientific ER0452 
GoTaq qPCR Master Mix Promega A6001 
NdeI NEB R0111S 
Proteinase K  Fisher Scientific  BP1700-100 
SexAI NEB R0605S 
T4 Ligase NEB M0202S 
Taq DNA polymerase and buffer  5 prime  2200010 
 
3.7 Buffers: 
 
Phosphate Buffered Saline (1x PBS, pH 7.4) 
The media supply center of the Bioinnovation Center, TU-Dresden provided PBS 
without magnesium and calcium. 
 Final Concentration 
NaCl 137.0 mM 
KCl 2.7 mM 
Na2HPO4  10.0 mM 
KH2PO4  
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Lysis Buffer for ES cells 
 Final Concentration 
1M Tris, PH 7.5 5mM 
0.5M EDTA 5mM 
1M NaCl 5mM 
N-Lauroylsarcosine 17mM 
Proteinase K (added immediately prior to use) 1 mg/ml 
Reagents were dissolved in sterile H2O with a final volume of 0.5L and autoclaved. 
Proteinase K was added directly before use. 
 
LB medium 
The media supply center of the Bioinnovation Center, TU-Dresden provided PBS 
without magnesium and calcium. 
 Final Concentration 
Tryptone 10 g/L 
Yeast Extract 5 g/L 
NaCl 5 g/L 
 
3.8 Synthetic Oligonucleotides 
qPCR Primers  
Scn10a Mouse End F GAACCAATAGCAACCACCCT 
Scn10a Mouse End R GCGTTGCAACATGTAGTTCC 
Scn10a Human Start F ACCAAGAAGAGAAGCCTCGG 
Scn10a Human Start R ACTAGTAGCTCTTACCCGGTG 
Scn10a Human End F AGCCAACTTTGTCACGTCTC 
Scn10a Human End R GGATGACTCTGAAGAGCGTT 
MRRF F ATCGACAGAGGGCTTGCATC 
MRRF R GCAGCTGTACACTGAAAACCA 
HATI F CCCATCATGCATGTAAACGGT 
HATI R GAGTTTGCCGTGAGTTCAGC 
  
HPRT Repair ODN  
Asymmetric Oligo Sense 
GTGGTGGTTTTATTTACCATTAAATGTCTCTTTTC
TTTTTAAAAGGATATAATTGACACTGGTAAAACA
ATGCAAACTTTGCTTTCCCTGGTTAAGCAGTACA
GCCCCAAAATGGTTAAGGTTGCAA 
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Asymmetric Oligo 
Antisense 
TTGCAACCTTAACCATTTTGGGGCTGTACTGCTT
AACCAGGGAAAGCAAAGTTTGCATTGTTTTACCA
GTGTCAATTATATCCTTTTAAAAAGAAAAGAGAC
ATTTAATGGTAAATAAAACCACCAC 
HPRT-ss50bp-Sense 
AATGCAAACTTTGCTTTCCCTGGTTAAGCAGTAC
AGCCCCAAAATGGTTA 
HPRT-ss50bp-Antisense 
TAACCATTTTGGGGCTGTACTGCTTAACCAGGGA
AAGCAAAGTTTGCATT 
HPRT-ss100bp-Sense 
AGGATATAATTGACACTGGTAAAACAATGCAAA
CTTTGCTTTCCCTGGTTAAGCAGTACAGCCCCAA
AATGGTTAAGGTTGCAAGGTATGTATGCCACTT 
HPRT-ss100bp-
Antisense 
AAGTGGCATACATACCTTGCAACCTTAACCATTT
TGGGGCTGTACTGCTTAACCAGGGAAAGCAAAG
TTTGCATTGTTTTACCAGTGTCAATTATATCCT 
 
3.9 BACs 
mScn10a BAC RP24-303H7  
hSCN10A BAC RP11-1400P20 
Hprt BAC RP23-13N1 
P1-amp mou-hum scn10a (Shenbiao Hu) 
 
3.10 Plasmids 
HPRT repair vectors  
pBR322-amp-HPRT-200bp This Work 
pBR322-amp-HPRT-500bp This Work 
pBR322-amp-HPRT-1kb This Work 
pBR322-amp-HPRT-2kb This Work 
pBR322-amp-HPRT-5kb This Work 
pBR322-amp-HPRT-10kb This Work 
pBR322-amp-HPRT-1kb-200bp This Work 
pBR322-amp-HPRT-1kb-500bp This Work 
pBR322-amp-HPRT-1kb-2kb This Work 
pBR322-amp-HPRT-1kb-5kb This Work 
pBR322-amp-HPRT-1kb-10kb This Work 
pBR322-amp-Hprt-PGK-neo-5kb This Work 
pBR322-amp-HPRT-1kb-isogenic This Work 
  
HA With Engineered Mutations  
pBR322-amp-Hprt-(-5bp) This Work 
pBR322-amp-Hprt-1kb-BssSI This Work 
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pBR322-amp-Hprt-1kb-BssSI-ndeI-(-883) This Work 
pBR322-amp-Hprt-1kb-BssSI-ndeI-(-701) This Work 
pBR322-amp-Hprt-1kb-BssSI-ndeI-(-464) This Work 
pBR322-amp-Hprt-1kb-BssSI-ndeI-(-181) This Work 
pBR322-amp-Hprt-1kb-BssSI-(-5bp)-(-883) This Work 
pBR322-amp-Hprt-1kb-BssSI-(-5bp)-(-701) This Work 
pBR322-amp-Hprt-1kb-BssSI-(-5bp)-(-464) This Work 
pBR322-amp-Hprt-1kb-BssSI-(-5bp)-(-181) This Work 
  
TALEN expression vectors  
pCAG-T7-TALE-FokI-ELD destination Addgene 40131 
pCAG-T7-TALE-FokI-KKR destination Addgene 40132 
pCAG-T7-TALE-FokI-ELD Start 1 This Work 
pCAG-T7-TALE-FokI-KKR Start 2 This Work 
pCAG-T7-TALE-FokI-ELD Middle 1 This Work 
pCAG-T7-TALE-FokI-KKR Middle 2 This Work 
pCDNA3.1(-)-pTAL3 This Work 
pCDNA3.1(-)-pTAL3 neo del ccdb-hyg-17aa This Work 
  
Rep Vectors  
pCMV-RabCht-Rep Kuhn Lab 
pCMV-ccdb-hyg-Rep This Work 
pCMV-Scn10a Start-Rep This Work 
pCMV-Scn10a Middle-Rep This Work 
  
gRNA expression plasmids  
pBR322-U6-cm-ccdb-tracrRNAnew-amp Stewart Lab 
pBR322-U6-Hprt 6-1-tracrRNAnew-amp This Work 
pBR322-U6-Hprt 67-tracrRNAnew-amp This Work 
pBR322-U6-Hprt 76-tracrRNAnew-amp This Work 
pBR322-U6-Hprt 67/76-4-tracrRNAnew-amp This Work 
pBR322-U6-neo5-tracrRNAnew-amp This Work 
pBR322-U6-PGK1-tracrRNAnew-amp This Work 
pBR322-U6-PGK8-tracrRNAnew-amp This Work 
pBR322-U6-Hprt C15-tracrRNAnew-amp This Work 
pBR322-U6-Hprt C18-tracrRNAnew-amp This Work 
pBR322-U6-Scn10a 3-tracrRNAnew-amp This Work 
pBR322-U6-Scn10a 7-tracrRNAnew-amp This Work 
  
Cas9 Expression Vector  
pBR322-CAGGS-NLS-FLAG-linker-hCas9-IRES-puro Stewart Lab 
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Ligation vectors  
pBR322-amp-ligation vector SD This Work 
pBR322-amp-ligation vector OD This Work 
  
p15a-hyg-ccdb-cm Stewart Lab 
p15a-cm-HPRT-EcoRV Stewart Lab/Jun Fu 
pR6K-PGK-EM7-neo Stewart Lab 
 
3.11 gRNA Sequences 5’-3’ PAM 
Hprt 6-1 TGGGGCTGTACTGCTTAACC AGG 
Hprt C15 TTTGCATTACAGCCCCAAAA TGG 
Hprt C18 TTTGGGGCTGTACTGTACCA GGG 
Hprt 67 CTGAGGTAGTTCTAGATCCA AGG 
Hprt 76 CCTCTTAGGAGTCTAAAGTA GGG 
Hprt 67/76-4 CTAGATTTTAGACTCCTAAG AGG 
Neo-5 TGAGAGCTCCCTGGCGAATT CGG 
Pgk-1 ATGCGCTTTAGCAGCCCCGC TGG 
Pgk-8 TAGGGGAGGCGCTTTTCCCA AGG 
Scn10a g3 GGTAGTTCCCACGGACCCAA AGG 
Scn10a g7 ACGGTTCACTCCAGAGTCGC TGG 
 
3.12 TALEN sequences: 
Scn10a Start TALEN 21 
Tal 1 Length: 29 GGTTATTTTCCTCCCAGAAGAGTGTAAAT 
1.1: NN_1 NG_2 NG_3 NI_4 NG_5 NG_6 NG_7 NG_8 HD_9 HD_10 pFUSA_30A 
1.2: NG_1 HD_2 HD_3 HD_4 NI_5 NN_6 NI_7 NI_8 NN_9 NI_10 pFUSA_30B 
1.3: NN_1 NG_2 NN_3 NG_4 NI_5 NI_6 NI_7 pFUS_B7 
LR: pLR_NG 
 
Tal 2 Length: 28 AGATGGAGTTCCCCTTTGGGTCCGTGGG 
2.1: HD_1 HD_2 HD_3 NI_4 HD_5 NN_6 NN_7 NI_8 HD_9 HD_10 pFUSA_30A 
2.2: HD_1 NI_2 NI_3 NI_4 NN_5 NN_6 NN_7 NN_8 NI_9 NI_10 pFUSA_30B 
2.3: HD_1 NG_2 HD_3 HD_4 NI_5 NG_6 HD_7 pFUS_B7 
LR: pLR_NG 
 
 
Spacer Length: 21 
Spacer Sequence: CCTTCCCCAAGAAGAATGAGA NN  
 
Scn10a Middle TALEN 13 
Tal 1 Length: 16 GCCCACCCTGCTTGAT 
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1.1: NN_1 HD_2 HD_3 HD_4 NI_5 HD_6 HD_7 HD_8 NG_9 NN_10 pFUS_A 
1.2: HD_1 NG_2 NG_3 NN_4 NI_5 pFUS_B5 
LR: pLR_NG 
 
Tal 2 Length: 16 AAGTACCTGATATGGG 
1.1: HD_1 HD_2 HD_3 NI_4 NG_5 NI_6 NG_7 HD_8 NI_9 NN_10p FUS_A 
1.2: NN_1 NG_2 NI_3 HD_4 NG_5 pFUS_B5 
LR: pLR_NG 
 
 
Spacer Length: 13 
Spacer Sequence: CAGCTTAGCCCAG 
3.13 ES Cell Culture 
3.13.1 Cell Lines: 
Mouse Embryonic Fibroblasts (MEF or Feeders): isolated from 13.5dpc embryos 
E14Tg2a: mESC with a 129 male genetic background. Feeder independent 
R1: mESC with a 129 male genetic background. Feeder dependent, but weaned for 
several experiments 
HEK 293: Human embryonic kidney cells  
3.13.2 MEF Cultivation and Inactivation: 
MEFs from E13.5 embryos were expanded in DMEM with 4.5 g/l glucose 
supplemented with 10 % heat-inactivated FCS, 2mM L-glutamine, and 1 % P/S. 
Confluent cell layers were inactivated by mitomycin C (10 mg/ml) to prevent further 
cell divisions, and flash frozen at -80C before long term storage in liquid nitrogen. 
MEFs were thawed and plated at 80 % confluency 24 hours before seeding mESC. 
3.13.3 mESC Culture 
Feeder‐ independent ES cell lines were kept in an undifferentiated state by culturing 
them in standard ES medium. ES cells were kept at 37°C and 5 % CO2 and passaged 
every 48-72 hours to avoid confluent growth and differentiation.  
 
Feeder-dependent ES cell lines were kept in an undifferentiated state in culture at 
37°C and 5 % CO2. Mitomycin C inactivated MEFs were plated on gelatinized cell 
culture dishes for 24 hours in MEF medium. After 24 hours, ES cells were plated on 
the feeders in mESC medium. The cells were passaged every 48-72 hours to avoid 
confluency and differentiation. 
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3.13.4 mESC Passaging 
ES cells were passaged by trypsinization (Trypsin 2x + G) for 5 minutes at 37°C. 
Trypsin was neutralized by addition of standard mESC medium and the cells clumps 
were manually dispersed by pipetting to form a single cell suspension. The cells were 
then distributed to new dishes at an appropriate concentration. 
3.14 Long Term mESC Storage 
Cell lines were flash frozen at -80C and transferred to liquid nitrogen for long term 
storage in culture medium containing 15 % FCS and 10 % DMSO.  
3.15 Cell culture reagents and media 
0.1 % Trypsin (for mESC) 
 Final Concentration 
PBS 1x 
2.5 % Trypsin 0.1 % 
Chicken Serum 1 % 
EDTA 0.2 mg/ml 
D-glucose 1 mg/ml 
 
mES Medium (FCS+LIF) 
 
 Final Concentration 
DMEM+ GlutaMax  
FCS 10 % 
2-mercaptoethanol 100 mM 
L-glutamine 2 mM 
100 mM Sodium Pyruvate 1 mM 
100x non-essential amino acids 1x 
Stewart lab recombinant LIF 1 ml/500 ml 
Additional if 2i conditions 
PD-0325901 1 M 
CT-99021 3 M 
 
Beta-mercaptoethanol Solution 
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7 l of -mercaptoethanol was added to 10 ml of PBS and filter sterilized. Aliquots 
were stored at -20C. 
3.16 mESC Transfection: 
3.16.1 ES cell electroporation: 
Actively growing mESC were rinsed with 1x PBS, trypsinized, collected with mESC 
medium in a 15 ml Falcon tube, pelleted by centrifugation, and washed once with 
PBS. Unless otherwise indicated, 5x106 cells were resuspended in 800 l of cold PBS 
mixed with DNA. The electroporation was performed in a chilled 4 mm 
electroporation cuvette with a Gene Pulser X-Cell (BioRad) using the exponential 
settings (250 V, 500 F). The cuvettes were left for 5 min at RT after electroporation 
and the contents were transferred to a 15 ml Falcon tube with 5 mL pre-warmed mES 
medium. Cell clumps were distributed by manual pipetting, and the cell suspension 
was distributed to gelatinized 10 cm culture plates containing 9 ml pre-warmed 
medium. After 24 hours, fresh ES medium supplemented with appropriate selection 
was added and the selection medium was changed frequently until colonies were 
visible for picking (using a microscope) or counting after staining (by eye). 
3.16.2 ES cell nucleofection: 
Actively growing mESC were rinsed with 1x PBS, trypsinized, collected with mESC 
medium in a 15 ml Falcon tube, pelleted by centrifugation, and washed once with 
PBS. 2x106 cells were resuspended in 100 l of Nucleofection mix (2:9 mix of 
supplement 1 with mES Nucleofector solution (Lonza) and RNP. The RNP was 
formed by mixing 7.5 g Cas9 protein (MPI-CBG) and 7.5 g in vitro transcribed 
mRNA in H2O for 10 min at RT. The cell-RNP suspension was transferred to 
nucleofection cuvettes (Lonza) and the nucleofection was carried out using a 
Nucleofector II device, program A-013 as recommended by the manufacturer. The 
contents of the cuvettes were immediately transferred to a 15 ml Falcon tube with pre-
warmed mES medium. Cell clumps were distributed by manual pipetting, and the cell 
suspension was distributed to gelatinized 10 cm culture plates containing 9 ml pre-
warmed medium. After 24 hours, fresh ES medium supplemented with appropriate 
selection was added and the selection medium was changed frequently until colonies 
were visible for counting after staining (by eye). 
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3.16.3 ES cell lipofection: 
An appropriate amount of circular plasmid or BAC DNA was lipofected into 2.5x105 
mES cells seeded in 6-well plates 24 h before. The DNA was added into 300 μl Opti-
MEM with Glutamax and 2.5 μl of Plus Reagent was added and incubated 5 min at 
RT. 6.25 μl of Lipofectamine LTX was added and the solution was carefully mixed 
by inversion. After 30 min RT incubation, the lipofection mix was added dropwise to 
the cells in 3 ml of fresh mES medium and incubated overnight. 
3.17 T7E1 
200 ng of column purified PCR product was denatured and re-annealed in a PCR 
cycler. A 20 l reaction with 1x NEB buffer 2 and 1l T7E1 enzyme was incubated 
for 1 hour at 37C and the digest was run on a 1 % agarose gel to check for cleavage 
products.  
3.18 In vitro transcribed RNA 
In vitro transcribed RNA was made using the manufacturer’s suggestions for the 
Mega Shortscript T7 kit. PCR primers were designed with a T7 promoter and a 
‘guard’ integrated into the forward primer. A PCR was performed with a high fidelity 
polymerase, the product was extracted from a gel, and 1 g of the DNA was used for 
the transcription reaction (using the buffer, dNTPs and T7 enzyme from the kit). The 
reaction was left to run overnight at RT. 1 l of Turbo DNAse was added and the 
reaction was incubated at 37ºC for 15 minutes. The RNA was then purified twice with 
phenol/chloroform and precipitated with sodium acetate and EtOH. The RNA pellet 
was dissolved in H2O and stored at -80ºC. 
3.19 Quantitative PCR (qPCR) 
Quantative PCR amplifications were completed in a Mx3000P or Mx3005P multiplex 
PCR instrument with the following reaction mixtures and thermal profile. 
 
 20 l Final conc. 
ddH2O 7,4 l - 
2x GoTaq qPCR Master Mix 10 l 1x 
10 M Primer 1 0.8 l 100 nM 
10 M Primer 2 0.8 l 100 nM 
DNA 1 l 10 ng/ 20l 
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 Temperature Time 
Initial denaturation 95ºC 5 s 
 Denature 95ºC 10 s 
40 Cycles Anneal 62ºC 20 s 
 Elongation 72ºC 30 s 
 95ºC 1 m 
Dissociation curve 62ºC 30 s 
 0.5ºC steps 62ºC - 95ºC 30 s 
 
The analysis of qPCRs was performed in triplicate, and the cycle threshold (Ct) values 
were normalized against the Ct of an internal control (MRRF or Nxt2). Fold change 
was calculated using the ΔΔCt method(121): 
 
2 - ΔΔCt 
ΔΔCt = (Ctgene – avg. Cthousekeeping)sample - (avg. Ctgene – avg. Cthousekeeping)control 
3.20 X-Gal staining: 
6-well plates with attached cells were washed once with 1x PBS, then 2 ml fixative 
solution was added to each well, followed by a two-minute incubation at room 
temperature. After aspiration of the fixative solution, the wells were washed three 
times with 1x PBS and incubated overnight at 37C with 2 ml staining solution. The 
next day, the wells were washed once with 1x PBS and blue staining was documented 
with a stereomicroscope. 
 Fixative Solution  Staining Solution 
675 l Formaldehyde [37 %] 25 l MgCl2 [1 M] 
50 l Glutaraldehyde [25 %] 1.25 ml Potassium Ferricyanide [50 mM] 
11.78 ml PBS 1.25 ml Potassium Ferrocyanide [50 mM] 
12.5 ml  9.9 ml PBS 
  62.5 l X-Gal [200 mg/ml] in DMF* 
  12.5 ml  
*heat staining solution to 50C before adding X-Gal to prevent crystallization 
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3.21 Quantitative -Gal assay: 
Cells were washed with PBS and harvested by scraping in 1x PBS, transferred to 1.5 
ml Eppendorf tubes and centrifuged at 4,000 rpm for four minutes at 4C. The liquid 
supernatant was aspirated and the cell pellets were resuspended in 100 l Extraction 
Buffer and disrupted by three cycles of flash freezing in liquid nitrogen and thawing 
in a warm water bath. The samples were centrifuged at 12,000 rpm for 15 minutes at 
4C to remove cell debris. The protein concentration was measured on the nanodrop, 
and the protein was diluted to 40 g. The protein extracts were mixed with 800 l of 
Solution I followed by 200 l of Solution II. The samples were thoroughly mixed by 
vortexing and incubated in the dark at 37C for 1 hour (until the yellow color is 
visible). The reaction was stopped by the addition of 500 l [1 M] NaCO3. The 
mixture was transferred into plastic cuvettes for measurement of absorbance at 420 
nm using a UV/Visible Spectrophotometer. 
Extraction Buffer Solution I Solution II 
0.25 M Tris-HCl (pH 7.8) 1 M Na2HPO4*2H2O 1 M Na2HPO4*2H2O 
100 mM DTT 1 M NaH2PO4*2H2O 1 M NaH2PO4*2H2O 
100 mM PMSF 2 M KCl 2 mg/ml ONPG 
(Adjust pH to 7.0) 1 M MgCl2  
 
3.22 Genomic DNA extraction: 
ES cells were grown at high density in a 24 well tissue culture plate for DNA 
extraction. Cells were washed with PBS and incubated with 200 μl of lysis buffer at 
55 °C overnight in a humid box. Genomic DNA was precipitated from the lysis mix 
ethanol precipitation with 400 l of NaCl and 100% EtOH. The DNA was 
precipitated in the plate according to the protocol described in “Genomic DNA 
Microextraction: A Method to Screen Numerous Samples”(122). 
3.23 HPRT assay: 
mESC were grown on gelatinized cell culture dishes. The medium was discarded, and 
the plates were washed with PBS. The mESC colonies were fixed in 4 mL of 80 % 
EtOH for 10 minutes and then stained in 4 ml Coomassie blue staining solution (500 
ml: 362.5 ml H2O, 100 ml MeOH, 37.5 ml acetic acid, 0.25 g Coomassie G250) for 
10 minutes. The staining solution was decanted (and saved to be reused) and the 
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culture dishes washed with H2O and air-dried. The stained colonies were manually 
counted. 
 
 
Figure 4 Quantitative Hprt rescue assay Cells with a damaged Hprt were transfected with repair 
constructs or ODN and Cas9/gRNA. After 24 hours, HAT supplemented media was applied to the 
plates to select for cells with a repaired Hprt. After 10 days, the colonies were fixed and counted to 
provide a quantitative evaluation of nuclease assisted targeting efficiency.  
3.24 Southern assay: 
Genomic DNA (5 -10 μg per ES cell clone) was digested with NdeI restriction 
enzyme and the digested DNA bands were separated by electrophoresis through a 0.8 
% agarose gel in 1x TBE buffer. Gels were run at low voltage to allow for proper 
band separation. Following electrophoresis gels were denatured twice with denaturing 
buffer for 15 minutes and once with neutralizing solution for 20 minutes. The DNA 
was transferred via capillary action to a nylon membrane by blotting with 20x SSC 
overnight. After blotting, the membrane was rinsed with 6x SSC and the DNA was 
fixed to the membrane by UV crosslinking. 
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Denaturation Buffer for Southern blotting 
 Final Concentration 
NaCl 1.5 M 
NaOH 0.5 M 
Reagents were dissolved in sterile H2O with a final volume of 1 L. 
 
Neutralization Buffer for Southern blotting 
 Final Concentration 
Tris 1 M 
NaCl 1.5 M 
 
*The Tris and NaCl were dissolved 800 ml of H2O, the pH value was adjusted to pH 
7.4 with HCl and the final volume was adjusted to 1 L with H2O. 
 
20 x SSC 
 Final Concentration 
NaCl 3 M 
Sodium Citrate 0.3 M 
Reagents were dissolved in 800 ml H2O, pH adjusted with HCl to pH 7.0, and the 
final volume was adjusted to one liter and sterilized by autoclaving. 
 
Random prime DNA labeling was achieved using the HighPrime Kit. Template DNA 
(50 – 100 ng) from a gel extracted PstI fragment of the neo gene was denatured in 11 
μl distilled water for 10 minutes at 99°C and chilled on ice immediately to prevent 
renaturation. HighPrime (4 μl) and radioactive [α32P] dCTP (5 μl) were added and 
samples were incubated at 37°C for 1 hour. Unincorporated dNTPs were removed by 
filtration with Sephadex G50 Quick Spin Columns. Radiolabelled DNA probes were 
loaded onto Quick Spin Columns and centrifuged for 4 minutes at 1,000 x g. Purified 
radiolabelled DNA probes were used immediately. 
 
Nylon membranes with fixed target DNA were rinsed with 6x SSC and rolled into 
hybridization bottles. Prehybridization solution for southern blots was pre-warmed to 
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37°C before use. 8 ml CG-prehybridization solution was added to each hybridization 
tube and membranes were prehybridized for 1 hour at 63°C. Radio-labeled DNA 
probes were heat-denatured at 99°C for 10 minutes and chilled rapidly on ice. 
Denatured probes were added to the prehybridization solution and membranes were 
hybridized at 63 °C overnight. After hybridization, membranes were washed 2x for 20 
minutes with CG washing buffer at 65°C to remove residual unbound probe and 
probes that were not specifically bound to the membrane. The washed membranes 
were covered with plastic wrap and exposed to X-ray films overnight before detection 
with the FLA3000. 
 
CG Wash Solution 
 Final Concentration 
Na2HPO4* 2H2O 20 mM 
20 % SDS 1 % 
0.5 M EDTA pH 8.0 1 mM 
 
Reagents were dissolved in sterile H2O with a final volume of 1 L.  
 
CG Hybridization Solution 
Stock solution Final concentration Amount for 0.5 liter 
 Final Concentration 
Na2HPO4* 2H2O, pH 7.2 0.25 M 
20 % SDS 7 % 
10 % Bovine serum Albumin (BSA) 1 % 
EDTA, pH 8.0 1 mM 
H2O  
Reagents were mixed, filtered with a 0.33 M filter, aliquoted, and stored at -20C 
 
3.25 Large scale bacterial DNA preparation: 
Large-scale extractions of plasmid DNA were made using Qiagen reagents from 250-
500 ml overnight cultures in LB supplemented with appropriate antibiotics following 
the manufactures directions. Briefly, the cells were pelleted and resuspended in 10 ml 
of Qiagen buffer P1, then mixed with 10 ml of Qiagen Buffer P2 and incubated at 
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room temperature for 5 minutes to lyse the cells. 10 ml of Qiagen Buffer P3 was 
added to the mixture, and the mixture was incubated for 20 minutes on ice. The 
sample was briefly centrifuged to clear the lysate, then filtered through a Whatman 
filter into a Qiagen 500 column that was equilibrated with Qiagen Buffer QBC. The 
column was washed twice with 30 ml of Qiagen Buffer QC and eluted with 15 ml of 
Qiagen Buffer QF. 10.5 ml of isopropanol was added, the solution was vigorously 
mixed, and the sample was centrifuged for 1 hour at 9,000 rpm. The DNA pellet was 
washed with 70% ethanol, air dried and resuspended in water to an appropriate 
concentration. 
 
Large-scale extractions of BAC DNA were made using the MN BAC 100 kit from 
500 ml overnight cultures in LB supplemented with appropriate antibiotics following 
the manufactures directions. Briefly, the cells were pelleted and resuspended in buffer 
20 ml of S1, then mixed with 20 ml of buffer S2 and incubated at room temperature 
for 5 minutes to lyse the cells. 20 ml of buffer S3 was added to the mixture, and the 
mixture was incubated for 20 minutes on ice. The sample was briefly centrifuged to 
clear the lysate, then filtered through a Whatman filter into a BAC 100 column that 
was equilibrated with buffer NBT. The column was washed twice with 30 ml of 
buffer N3 and eluted with 15 ml of pre warmed buffer N5. 10.5 ml of isopropanol was 
added, the solution was vigorously mixed, and the sample was centrifuged for 1 hour 
at 9,000 rpm. The DNA pellet was washed with 70 % ethanol, air dried and 
resuspended in water to an appropriate concentration. 
3.26 Small scale bacterial DNA preparation: 
Plasmid and BAC DNA was extracted by alkaline lysis mini prep. In general, a 2 mL 
culture of LB supplemented with appropriate antibiotics was inoculated with a 
bacterial culture and left to grow overnight at an appropriate temperature (30 or 37C) 
in a thermoshaker at 950 rpm. The next day, the culture was centrifuged at 13,200 
rpm for 1 min to pellet the bacteria. 200 L of Qiagen buffer P1 was added and the 
pellet resuspended. Then 200 L of Qiagen buffer P2 was added and the mixture was 
gently mixed to allow lysis of the cells. 200 L of Qiagen buffer P3 was added to the 
mixture and gently mixed to neutralize the solution. The samples were then 
centrifuged for 10-20 min to pellet the lysed cell components. The DNA containing 
supernatant was then transferred to a new microcentrifuge tube containing 500 L 
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isoproponal, and the samples were vigorously mixed. The samples were then 
centrifuged at 13,200 rpm for 20 minutes to pellet the DNA. The supernatant was 
decanted, and the DNA pellet gently washed with 500 L 70 % EtOH. Finally, the 
pellet was then left to dry before resuspension in water. 
3.27 Restriction endonuclease digest: 
Restriction Endonuclease digestion of double stranded DNA was performed 
according to the instructions of the manufacturer using the provided buffer. 
3.28 Bacterial electroporation: 
DNA was transfected into bacterial cells via electroporation. A 1 mL culture was 
grown to confluency (usually overnight) in LB supplemented with the appropriate 
antibiotics at the appropriate temperature (30 or 37C) in a thermoshaker at 950 rpm. 
From the confluent culture, 30 L was used to inoculate tubes with a punctured lid 
containing 1.4 mL fresh LB supplemented with the appropriate antibiotics. After 2 
hours growth at 30C shaking at 950 rpm, the cultures were induced with arabinose (if 
applicable) and transferred to 37C shaking at 950 rpm for 45 min. The cultures were 
then centrifuged at 4C at 9,000 rpm for 30 s, the supernatant decanted, and the cell 
pellet resuspended in 1mL cold water. The samples were then centrifuged a second 
time (4C,10,000 rpm, 30 sec) the supernatant decanted, and the pellets resuspended 
in 1 mL cold water. The samples were centrifuged a final time (11,000 rpm, 4C, 30 
sec) and all but ~30 L was decanted from the tubes. The pellet was resuspended in 
this ~30 L, mixed with DNA and transferred to a chilled 1 mm electroporation 
cuvette. The cuvette was immediately pulsed in a Biorad electoporator at 1250 V 
aiming for a time constant between 3.0 and 6.0 ms. 
 
3.29 Ethanol DNA precipitation: 
To precipitate (and therefore purify and concentrate the DNA), 1/10 of the sample 
volume of buffer P3 (or 3M NaAc) and 3x the volume of 100% ice cold EtOH were 
added to the DNA solution. The sample was thoroughly and gently mixed by 
inversion, and the tube was incubated at -20C for 1 hour or -80C for 5 minutes. The 
samples were then centrifuged at 20C at maximum speed and the pellet washed in 
70% EtOH and air dried. The DNA was then dissolved in water to an appropriate 
concentration. 
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3.30 PCR purification: 
PCR products were purified of primers, dNTPs, and PCR reagents using the 
QIAquick PCR purification kit (Qiagen) according to the manufactures instructions. 
Briefly, 5 volumes of binding buffer were mixed with the PCR reaction mixture. The 
mixture was applied to the QIAquick spin column, centrifuged, and the flow-through 
discarded. 10-25 l of water was added to the column, incubated for 5 minutes at RT 
and then centrifuged. The eluate was collected in a 1.5 ml micocentrifuge tube. 
3.31 Gel extraction: 
DNA fragments were separated by electrophoresis on agarose gels in 1x TBE. The 
desired band was visualized via excited blue light on the Dark reader and excised. 
DNA was extracted using the QIAquick gel extraction kit (Qiagen) according to the 
manufactures instructions. 
3.32 Gel electrophoresis: 
DNA was electrophoresed in TBE agarose gels with 0.8 % to 2 % agarose depending 
on the size of the desired fragment. Ethidium bromide was added to the gels at 100 
ng/ml to visualize the fragments, and the fragments were photographed using the 
syngene G:Box GeneSnap gel documentation system 
3.33 TALEN design and assembly: 
TALENs target sites were identified using the TALE-NT TALEN Targeter tool(123) 
by identifying the ideal region of TALEN cleavage and selecting the surrounding 
sequence. The sequence was submitted to the TALEN Targeter, which locates all 
possible TALEN target sites in the submitted sequence. From the list of identified 
TALEN targets, one TALEN pair was selected based on its proximity to the ideal 
cleavage site, it’s spacer length, and TAL length (with shorter, easier-to-assemble 
TAL effectors preferred with a minimum length of 16 RVDs. Some submitted 
sequences returned many possible target sites, while others had very few. The chosen 
target sites were then compared against the mouse genome for potential off-target 
effects using the TAEN-NT tool.  
 
Our lab used the kit designed and graciously provided by the Voytas lab.(123) TAL 
effector constructs were assembled as described using Golden Gate cloning. The 
Golden Gate method utilizes unique 4 bp overhangs (sticky ends) that are left by Type 
IIS restriction endonucleases. Briefly, RVD’s are assembled in two steps 1) assembly 
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of the RVDs into intermediary arrays and 2) joining of the intermediary arrays into a 
final TAL effector expression vector. 
 
First, the module plasmids that contain RVD’s 1-10 plus intermediate plasmid 
pFUS_A and RVDs 11-11+n with the appropriate pFUS_B are digested and ligated in 
the same reaction mixture by adding both BsaI and T4 ligase in the T4 reaction buffer 
and incubating in a thermocycler for 10 cycles of 5 min at 37C and 10 min at 16C. 
The enzymes are inactivated for 5 min at 50C followed by 5 min at 80C. To prevent 
linear, incomplete DNA fragments from recombining or self-circularizing, the 
mixture is treated with Plasmid Safe DNase for 1 hour at 37C. The reaction mixture 
is then dialyzed to remove buffer salts, electroporated into frozen competent GB05 or 
GB06 cells, and plated on LB-agar containing 60 g/mL spectinomycin, with Xgal 
and IPTG for blue/white screening. Several white colonies were picked, cultured, and 
checked by restriction digest and the junctions were sequenced to show correct 
assembly of the RVDs. 
 
In the second step, the intermediate, assembled RVD arrays, the appropriate last 
repeat (LR plasmid) and the expression vector are similarly digested and ligated, this 
time using the enzyme Esp3.I. The mixture was then dialyzed and electroporated into 
GB05 or GB06 cells and plated on LB supplemented with 100 g/mL ampicillin. 
Depending on the expression vector, the LB was additionally supplemented with X-
gal and IPTG (for blue white screening) or with ampicillin alone (for vectors where 
ccdb was replaced with RVDs). The resulting colonies are checked by restriction 
digest for correct assembly of the RVDs and sequence verified when possible. 
3.34 Plasmid Construction: 
3.34.1  gRNA design:  
gRNA recognition sequences were identified by the search engine provided by the 
Zhang Lab.(65) A DNA sequence was submitted to the CRISPR search engine to look 
for potential gRNA recognition sequences. The search engine scans the submitted 
sequence for possible CRISPR guides (20 nucleotides followed by a PAM sequence: 
NGG) and scans for potential off target matches throughout the selected genome. The 
program then rates the identified gRNA sequences based on their potential off target 
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effects. Only gRNAs with a high score (so low potential off target effects) were 
chosen for the experiments presented in this work.  
3.34.2  gRNA expression vector construction: 
gRNA expression vectors were assembled via recombineering. pBR322-U6-cm-ccdB-
tracrRNAnew-amp was digested with BstZ171 and NheI and the digest was run on a 
0.8 % agarose gel. The 3019 bp band was extracted from the gel and used for all 
further reactions. The fragment of pBR322-U6-cm-ccdB-tracrRNAnew-amp was co-
electroporated with a synthesized oligo that contained left and right HA to the vector 
and the 20 bp gRNA recognition site into competent bacterial cells that carried a 
psc101-ETgA plasmid. The cells were then plated on LB agar plates with ampicillin. 
The next day colonies were picked, and the plasmid DNA was extracted by alkaline 
lysis mini-prep and the insertion of the linear oligonucleotide was confirmed by 
restriction digest. Correct colonies were then confirmed by sequence analysis to 
ensure correct integration and the absence of mutations from the oligo. 
3.34.3 TALEN expression vectors: 
In order to shorten the linker, and decrease background from cloning, a ccdb-hyg 
cassette recombineering cassette was designed. Two synthetic ODNs (pTAL3-ccdb-F 
and pTAL3-ccdb-R) were purchased that had 50bp HA to the vector, an Esp3.1 site, 
and ~21bp PCR primers that amplified the ccdb-hyg portion of the p15A-hyg-ccdb 
plasmid. The pCDNA3.1(-)-pTAL3neo vector was linearized, and the purified PCR 
product and the linearized vector were co-electroporated into GB05-dir GyrA462 cells 
to produce pTAL3-ccdb-hyg-17aa. The cells were plated on LB-agar with 
Hygromycin selection and single colonies were picked after 24 hours. Positive 
colonies were verified first by restriction digest, then by sequence confirmation of the 
junctions to confirm correct integration of the cassette and the absence of mutation 
from the ODNs.  
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Figure 5 TALEN expression vectors The different TALEN vectors vary in their TAL C linker length, 
FokI nuclease sequence, and eukaryotic promoter. A) pCDNA3.1(-)-pTAL3 has a 236 aa linker and a 
CMV promoter. RVD insertions can be screened for with blue/white colonies. B) pCDNA3.1(-)-
pTAL3-ccdb-hyg has a shortened linker (17 aa) and RVD insertion has minimal background because of 
the ccdb selection. It has a CMV promoter and is derived from pCDNA3.1(-)-pTAL3. C and D) pCag-
t7-TALE-FokI-ELD/KKR destination vectors are obligate heterodimers. RVD insertion is screened for 
with blue/while colonies. The constructs have a 63 aa linker and a CAGGS promoter. 
 
3.34.4 CMV-Rep plasmid assembly: 
Two ODNs (LacZ ccdb F and LacZ ccdb R) were purchased that added 2x BstBI RE 
sites to PCR primers for the ccdb-hyg cassette from a p15A-ccdb-hyg plasmid 
template. The LacZ ccdb F primer additionally contained NheI and NaeI RE sites and 
the Lac ccdbR primer additionally contained AscI and KpnI RE sites to the plasmid 
could be used for additional downstream experiments. The PCR produced a 1633 bp 
product. This product, and the CMV-Rab-Rep plasmid from the Kuhn lab were 
digested with BstBI and the digestion products were purified by column and ligated 
overnight at 16C with T4 DNA ligase to produce a CMV-Rep-ccdb-hyg plasmid. 
The ligation product was electroporated into electrocompetent GB-dir GyrA462 cells 
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and the cells were plated on LB agar plates with hygromycin and ampicillin. Single 
colonies containing the correct plasmid were verified by restriction digest and 
sequence confirmed for absence of mutations from the ODN. This plasmid could then 
be used to insert the recognition sequence of other TALEN pairs and used for in vivo 
screening of TALEN cleavage efficiency. 
 
ODNs were then purchased that had the Scn10a Start and Scn10a Middle TALEN 
recognition sequences flanked by 2x NaeI and 2x KpnI RE sites. The Scn10a-Start-
Rep-Ins and the Scn10a-Middle-Rep-Ins ODNs and the CMV-Rep-ccdb-hyg plasmid 
were digested with NaeI and KpnI and the digestion products were column purified. 
The purified products were ligated using T4 Ligase overnight at 16C and the ligation 
products were electroporated into GB05 cells to produce CMV-Scn10a Start-Rep and 
CMV-Scn10a Middle-Rep. Positive colonies were screened by restriction digest and 
the absence of mutations was confirmed by sequencing.  
3.34.5 Subcloning Hprt repair vectors: 
psc101-A was electroporated into electrocompetent bacterial cells containing the 
RP23-13N1 BAC (CHORI). The cells with the BAC + psc101-A were plated on 
LB agar plates with chloromphenical and tetracycline. The plates were grown 
overnight at 30C. Recombineering oligos that contained a 50 bp HA to the BAC 
sequence and 21 bp PCR primers were used to amplify a pBR322-amp cassette from a 
pBR322-amp-ccdb-hyg plasmid. The subcloning back-bone PCR was electroporated 
into electrocompetent BAC + psc101-A that had the recombineering proteins 
produced after induction with L-arabinose. After recovery, the cells were plated on 
LB agar plates with ampicillin. Single colonies were grown, the plasmid DNA 
extracted by alkaline lysis mini prep and subclones of Hprt were confirmed by 
restriction digest and sequence analysis of the junctions to ensure no mutations were 
inserted from the ODNs. 
3.34.6 Insertion of a PGK-neo-cassette into Hprt exon 6: 
ODN (Quad HPRT Neo R and Quad HPRT PGK F) were purchased that contained 50 
bp HA to the RP23-13N1 and PCR primers to the pR6K-PGK-em7-neo plasmid. The 
HA to the BAC were designed such that 43 bp of Hprt exon 6 and was deleted upon 
insertion of the PGK-neo cassette which also caused a frameshift to ensure a KO 
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phenotype. A 1604 bp PCR product was amplified and column purified. 
Recombineering proficient bacterial cells with the Hprt containing RP23-13N1 BAC 
+psc101-A were electroporated with a purified PCR product to produce RP23-
13N1-PGK-neo cells. The cells were plated on LB agar plates with ampicillin and 
kanamycin. Single colonies were grown, the plasmid DNA extracted by alkaline lysis 
mini prep and the insertion of the PGK neo cassette was confirmed by restriction 
digest and sequence analysis of the junctions to ensure no mutations were inserted 
from the ODNs.  
 
The RP23-13N1-PGK-neo cells were then made electrocompetent and electroporated 
with psc101-A. The cells were plated on LB agar plates with chloromphenical and 
tetracycline and incubated at 30C. The cells were then grown and made 
recombineering proficient and electroporated with a back-bone PCR (Hprt-5kb-a and 
Hprt-5kb-b amplified pBR322-amp) to subclone a 10 kb segment of the Hprt gene 
(pBR322-amp-Hprt-Pgk-neo-5kb). The cells were plated on LB agar with ampicillin 
and kanamycin. Single colonies were grown, the plasmid DNA extracted by alkaline 
lysis mini prep and subcloning of the PGK neo cassette and surrounding DNA was 
confirmed by restriction digest and sequence analysis of the junctions to ensure no 
mutations were inserted from the ODNs. 
3.34.7 Subcloning of 672 fragment: 
The 672bp fragment of Hprt that was removed via CRISPR/Cas9 was subcloned from 
the Hprt containing RP23-13N1 BAC. ODNs (Ligation Vector OD F/R and Ligation 
Vector SD F/R) were designed that contained 50 bp HA to the BAC, the HPRT 67/76 
gRNA 4 recognition site in either the same direction (SD) or opposite (OD) direction 
as the gRNA genomic recognition site, and 21 bp PCR primers that amplified the 
pBR322-amp of a pBR322-amp-ccdb-hyg plasmid. Recombineering proficient 
bacterial cells with the Hprt containing RP23-13N1 BAC +psc101-A were 
electroporated with the purified PCR products to produce pBR322-Hprt-OD-672-
OD and pBR322-Hprt-SD-672-SD. The cells were plated on LB agar plates with 
ampicillin. Single colonies were grown, the plasmid DNA extracted by alkaline lysis 
mini prep and the insertion of the OD-672-OD and SD-672-SD was confirmed by 
restriction digest and sequence analysis of the junctions to ensure no mutations were 
inserted from the ODNs. 
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3.34.8 Engineered Mutations in Targeting Vector Homology Arms: 
A BssSI recognition site was inserted in Hprt exon 6 for simplified screening of 
recombination events. The substituted base pairs make a silent mutation. pBR322-
amp-HPRT-1kb was linearized with BsmI. GB05+ psc101ETA cells were made 
recombineering proficient by expression of the recombineering genes and the 
linearized pBR322-amp-HPRT-1kb gel extracted fragment was co-electroporated 
with purchased ODNs HPRT-LLHR BssSI-1n and HPRT-LLHR BssS1-2. The oligos 
contain 100mers that contain 50 bp HA to the pBR322-amp-HPRT-1kb plasmid and 
50 bp homology to each other, which includes the BssSI silent mutations. The cells 
were plated on LB agar plates with ampicillin to select for the pBR322-amp-Hprt-
1kb-BssSI cells. Single colonies were isolated, the plasmid DNA extracted by alkaline 
lysis mini prep and the insertion of the BssSI was confirmed by restriction digest and 
sequence analysis of the junctions to ensure no mutations were inserted from the 
ODNs. 
 
pBR322-amp-Hprt-1kb-BssSI cells were linearized with either BsmI, BstZ171, 
SexAI, EcoNI, or BsaBI. GB05+ psc101ETA cells were made recombineering 
proficient by expression of the recombineering genes and the linearized pBR322-amp-
HPRT-1kb-BssSI gel extracted fragment was co-electroporated with the appropriate 
LLHR oligo. The oligos either inserted a 6 bp NdeI or deleted 5 bp at the BsmI site 
(+61), the Bstz171 site (-181), the SexA1 site (-464), the EcoNI site (-701), or the 
BsaBI (-883) site. The ODNs contained 50 bp HA each side of the engineered 
mutation (100mers for the deletion ODNs, 106mers for the NdeI ODNs). The cells 
were plated on LB agar plates with ampicillin to select for the plasmids with 
engineered mutations. Single colonies were isolated, the plasmid DNA extracted by 
alkaline lysis mini prep and the insertion of the BssSI was confirmed by restriction 
digest and sequence analysis of insertion/deletion event. 
3.35 Design of the SCN10A humanization construct 
Shengbiao Hu, a former student in the Stewart lab developed an ambitious targeting 
exercise to humanize the mouse Scn10a gene. The SCN10A humanization construct is 
a complex design that includes three cassettes with multiple site-specific recombinase 
recognition sites. The construct was assembled via recombineering. The first cassette 
(Figure 6A) consists of a FRT flanked splice acceptor and lacZneo cassette and a loxP 
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site inserted into the first intron. This would allow for screening of the targeting event 
by lacZ staining. However, the lacZ cassette is driven by the endogenous promoter, 
and it was later determined that Scn10a is not expressed in mESC. Therefore, the 
LacZ gene and G418 selection cannot be used in mES cells. The LacZneo cassette can 
be deleted upon expression of the Flp recombinase leaving a LoxP site in the genome. 
A second cassette (Figure 6B) consisting of Rox flanked PGK-BSD and a loxP site 
was inserted after the second exon. As blasticidin (BSD) is driven by its own 
promoter, there is no need for endogenous expression of Scn10a to drive the BSD 
resistance. The PGK-BSD cassette can be deleted upon expression of the Dre 
recombinase, leaving a loxP site in the genome. The final cassette (Figure 6C) is a F3 
flanked hygromycin gene driven by a ubiquitin promoter and loxP site, which was 
inserted before the stop codon. Upon Flp expression, the F3 sites will recombine, thus 
deleting the hyg cassette and the LoxP site. Subsequent Cre expression will result in a 
KO phenotype while leaving the gene body intact. Alternatively, if the Cre 
recombinase is expressed before expression of the Flp recombinase, the LoxP sites 
will recombine, thus deleting the entire Scn10a gene body.  
 
 
Figure 6: Design of SCN10A Targeting Construct A) mScn10a gene is 85 kb and has 28 exons. B) 
hSCN10A is 96 kb and has 27 exons. Three cassettes were inserted into a BAC carrying the human 
SCN10A gene using standard recombineering methods C) Recombineering added 8 kb and 7 kb mouse 
HA to the human SCN10A gene resulting in a humanization targeting construct. 
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4 Results 
4.1 Humanization of the mouse Scn10a gene 
As TALENs were one of the first designer nucleases that could be easily assembled in 
the laboratory, our lab was excited to utilize this emergent technology to increase 
targeting efficiency in our own projects. Designer nucleases opened doors for 
experiments that were too ambitious without them, specifically the newly emergent 
TALENs as they were an affordable solution to ZFNs (CRISPR/Cas9 systems for 
gene targeting had not yet been published). An ambitious targeting exercise to 
humanize the mouse Scn10a gene, in which the 85 kb of the mouse genomic Scn10a 
gene would be replaced with a 96 kb human SCN10A gene (modified with three 
selection cassettes (section 3.35)) flanked by 7 kb and 8 kb homology arms was not 
possible, perhaps due to the large size of the construct. Several attempts were made to 
target the mouse genome in E14Tg2a mES cells using this construct, but were never 
successful. To overcome this challenge, TALENs offered an exciting method to 
increase targeting efficiency at the Scn10a locus.  
4.1.1 Strategy to increase targeting efficiency at the Scn10a locus with TALENs 
TALEN recognition sequences were identified at three separate locations in the mouse 
genome that did not recognize the TC or the human SCN10A gene. These TALENs 
recognized sequences present at the 5’(start), Middle, and 3’ (end) of the mouse 
Scn10a gene (figure 7A). TALENs were assembled using the Golden Gate system 
from the Voytas lab(123)  (section 3.33). The TALEN Start pairs, Middle pairs and 
the SCN10A targeting vector were then co-lipofected into E14Tg2a mES cells. To 
select for targeted cells, after 24 hours, medium supplemented with BSD was applied 
to the cells for 5 days, and then medium supplemented with HYG was put on the cells 
for an additional 5 days. After 10 days, there were no colonies on the plates. In an 
extended effort to overcome this issue, this experiment was repeated several times, 
with varying amounts of TC and TALEN constructs, and no targeted colonies were 
ever obtained. This indicated that either the Scn10a TALENs had poor cleavage 
efficiency, or there was a problem with the TC design. In an attempt to tackle these 
questions systematically, a more in depth examination of TALEN expression was 
necessary. 
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4.1.2 Evaluation two different TALEN pairs to test in vivo cleavage efficiency  
In order to validate the TALENs, an assay was performed to check for DNA cleavage 
in an in vivo experiment. Ten g of each TALEN Scn10a Start and Scn10a Middle 
Pairs (5 μg left and 5 μg right TALEN) were electroporated into 5x106 E14Tg2a cells 
which were plated into a 96 well plate, giving small bulk populations. After 30 hours, 
DNA was extracted from the wells and checked for cleavage with the T7E1 assay. 
Primer pairs (Scn10a Start -300F/ +200R and Scn10a Middle -300F/+200R) that 
amplified ~500 bp around the cut site were used to amplify genomic DNA extracted 
from the E14Tg2a cells. The PCR reaction was column filtered to remove primers and 
salts, and 200ng of each sample was denatured and re-annealed (figure 7B) in a PCR 
cycler, digested with T7E1 nuclease, and the digestion products were run on a 1 % 
gel. Positive and negative controls provided in the Surveyor nuclease kit were used to 
verify T7E1 cleavage, and undigested PCR product was loaded to show the original 
PCR band size (figure 7C). T7E1 cleavage of the mismatches produced by 
heteroduplex formation during reannealing would result in two bands, one at 200 bp 
and one at 300 bp. No cleavage product was observed for the bulk population of cells 
(figure 7C), which indicates that the cleavage efficiency of the TALENs was less than 
~5 %, which is the detection efficiency of the T7E1 assay.(124) As the two different 
TALEN pairs that were tested exhibited low in vivo cleavage efficiency, the next step 
was to try to improve TALEN efficiency in our culture conditions. 
 
Figure 7: TALEN Strategy and Validation with T7E1 assay A) TALEN design locations and primer 
pair location for amplification of genomic DNA B) Amplified genomic DNA is denatured and 
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reannealed. The T7E1 nuclease recognizes and cleaves non-perfectly matched heteroduplex DNA. C) 
T7E1 assay of amplified genomic DNA of E14tg2a cells transfected with different TALEN pairs. 
 
4.1.3 Modification of the TALEN expression vector to increase in vivo cleavage in 
mESC 
Mussolino et al.(63) indicated that the linker between the TAL RVDs and the FokI 
nuclease could affect the cleavage efficiency of the TALENs by FokI positioning, and 
suggested that a shortened C-terminal linker increased genome editing activity while 
reducing toxicity. The linker in the Voytas kit is 236 aa, which could be easily 
shortened to the suggested 17 aa, as the first 17 aa of the linker in the Voytas kit are 
supplied by the plasmid encoding the last repeat. This made shortening the linker very 
simple by removing the rest of the linker in the destination vector (pCDNA3.1(-)-
pTAL3). In addition to shortening the linker, cloning background was reduced by 
inserting a ccdb-hyg cassette into the final destination vector. CcdB is a toxin that 
poisons the gyrase-DNA complex, which blocks polymerase activity and leads to 
DSB. Cells that have a mutation in the gene encoding the A subunit of topoisomerase 
II (gyrA462) are resistant to the ccdb toxin.(125) Primers were designed that 
amplified a ccdb-hygromycin cassette (see section 3.43.3) and added Esp3.I 
restriction endonuclease sites and homology arm the pCDNA3.1(-)-pTAL3 final 
destination vector. Because of the integrated Esp3.I sites, the new destination plasmid 
with the short linker can be used in conjunction with the Voytas kit assembled RVDs. 
 
The RVDs of the Start and Middle TALENs were then inserted into the new TALEN 
expression vector with the shortened linker (pcDNA3.1 (-)-pTAL3-ccdb-hyg) using 
ligation of the cleaved Esp3.1 restriction endonuclease sites. Correct integration of the 
RVDs was confirmed by restriction digest and the junctions were sequence 
confirmed. The entire length of RVDs could not be sequence confirmed due to the 
repetitive nature of the RVD sequence. 
 
Variations of the FokI domain were reported to increase the specificity and activity of 
cleavage in ZFN,(126) and were an interesting possibility to increase TALEN 
cleavage, as well. The ELD/KKR mutations (ELD:KKR denotes 
Q486E,I499L,N496D and E490K,I538K,H537R) in FokI make it an obligate 
heterodimer, which reduces off-target effects. TALEN expression vectors were 
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obtained from Addgene that could be utilized with the Voytas Goldengate kit 
(Addgene 40132 and 40131). The RVDs for the Scn10a Start and Scn10a Middle 
TALEN pairs were ligated into the ELD/KKR vectors using Esp3.1. Correct cloning 
events were confirmed by restriction digest and the junctions were sequence 
confirmed. 
4.1.4 An in vivo test for TALEN cleavage 
A TALEN pair with established target cleavage in vivo via TALEN mRNA 
microinjection into the embryo(127) was provided to us by a colleague for a control 
along with system they used to confirm TALEN cleavage in vivo. The pCMV-Rab-
Rep plasmid is an unpublished construct that consists of the first 135 amino acids of 
the LacZ gene followed by a stop codon and the recognition site for the Rabcht 
TALEN pair followed by the last 1,022 aa of the LacZ gene (figure 8). This means 
that there is a repeat of 132 aa of the LacZ gene separated by the TALEN recognition 
site. Expression of the TALEN pair that recognizes the sequence that separates the 
LacZ gene causes a DNA DSB that is then repaired by the cell machinery. The 100 % 
homology between the replicated portions of LacZ form a perfect repair template to 
form a fully functioning LacZ gene that can be visualized by X-gal staining (figure 8).  
 
 
Figure 8 pCMV-Rep Vector Design The Rep plasmids consist of the first 135 amino acids of the 
LacZ gene followed by a stop codon and the recognition site for the a TALEN pair followed by the last 
1,022 aa of the LacZ gene. Expression of the TALEN pair that recognizes the sequence interrupting the 
LacZ gene causes a DNA DSB that is then repaired by the cell machinery. The homology between the 
replicated portions of LacZ forms a repair template to form a fully functioning LacZ gene. 
 
In order to use the pCMV-Rep vectors to test the efficiency of our Scn10a TALENs, 
the Rabcht TALEN recognition site was deleted from the pCMV-Rab-Rep plasmid (see 
section 3.34.4). Both the pCMV-Rep plasmid and purchased oligos with the Scn10a 
Start and Scn10a Middle recognition site flanked by NaeI and KpnI RE sites were 
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digested with NaeI and KpnI enzymes. Ligation of the digested products formed a 
transiently expressed plasmid that could test for in vivo cleavage of our Scn10a 
TALENs. The modified pCMV-Rep-ccdb-hyg plasmid can be modified to test any 
TALEN pair in vivo. With the inserted Scn10a Start and Middle TALEN recognition 
sites, the next step was to test the new TALEN expression plasmids for increased 
TALEN cleavage. 
4.1.5 Testing for in vivo TALEN cleavage 
Many of the published works that utilized TALENs worked with HEK293 cells. 
HEK293 cells are a human embryonic kidney cell line that was transferred with 
sheared human adenovirus and adenovirus DNA. The resulting cell line is 
hypotriploid with a modal chromosome number of 64. HEK293 cells are feederless 
and easy to transfect, making them a commonly used cell line for experiments. 
 
TALEN pairs and their corresponding pCMV-Rep vectors were lipofected into 
2.5x105 HEK293 cells to compare the cleavage efficiencies of the long linker supplied 
by the Voytas lab, the 17aa linker, and the ELD/KKR expression vectors. Cells were 
transfected with PBS as a negative control, a actin-LacZ expression vector as a 
transfection and staining control, and the pCMV-Rab-Rep plasmid with and without 
the Rabcht TALEN pair as a positive control for TALEN cleavage. Cells were also 
transfected with the pCMV-Scn10a-Start-Rep plasmid without TALENs and with the 
Scn10a Start RVDs in the long linker, 17aa, and ELD/KKR vectors and the pCMV-
Scn10a-Middle-Rep plasmid without TALENs, and with the Scn10a Middle RVDs in 
the long linker, 17aa and ELD/KKR vectors. After 72 hours, the cells were fixed and 
stained to test for LacZ expression. 
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Figure 9 Transfection of HEK293 cells with pCMV-Rep plasmids and different TALEN 
expression vectors HEK293 cells were transfected with PBS, a actin-LacZ expression vector, the 
pCMV-Rab-Rep plasmid with and without the Rabcht TALEN pair, the pCMV-Scn10a-Start-Rep 
plasmid without TALENs and with the Scn10a Start RVDs in the long linker, 17aa, and ELD/KKR 
vectors and the pCMV-Scn10a-Middle-Rep plasmid without TALENs, and with the Scn10a Middle 
RVDs in the long linker, 17aa and ELD/KKR vectors. 
 
As expected, there were no blue stained cells in the negative control (figure 9-1). 
There were blue staining cells in the cells transfected with a actin-LacZ expressing 
plasmid (figure 9-2) indicating efficient DNA transfection and cell staining. 
Surprisingly, there were some blue staining cells from all conditions transfected with 
the LacZ rep constructs (figure 9-3, 9-5, 9-9). This most likely comes from 
recombination of the LacZ repeated portions of the LacZ gene in the absence of DSB. 
The Rabcht TALEN pair shows an increase over the pCMV-Rab-rep alone (compare 
figure 9-3 to 9-4). The pCMV-Scn10a-Start-rep also shows some background staining 
(figure 9-5). However, the Scn10a Start RVDs in the ELD/KKR, 17aa and original 
TALEN expression vectors showed an increase in staining. An increase in blue 
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staining cells was not as evident with the Scn10a Middle TALENs, in any of the 
expression vectors (compare figure 9-9 to 9-10, 9-11, 9-12). 
 
As the staining results looked promising, the experiment was repeated in HEK293 
cells using a quantifiable -Gal assay. As there was no visible increase in staining 
with the Scn10a Middle TALEN pairs, those vectors were excluded from this 
experiment. As before, 2.5x105 HEK293 cells were lipofected with PBS as a negative 
control, a actin-LacZ expression vector as a transfection and staining control, and the 
pCMV-Rab-Rep plasmid with and without the Rabcht TALEN pair as a positive 
control for TALEN cleavage. Cells were also transfected with the pCMV-Scn10a-
Start-Rep plasmid without TALENs and with the Scn10a Start RVDs in the long 
linker, 17aa, and ELD/KKR vectors. After 72 hours, the cells were collected, pelleted 
and the quantifiable -Gal assay was performed. Expression of the repaired LacZ 
gene was tested for by X-Gal staining by measuring absorbance at 420nm. Again, as 
expected, there was no background from the cells or Lipofectamine, and a plasmid 
expressing LacZ showed a sharp increase in LacZ expression. The Rabcht TALEN pair 
showed an increase in LacZ expression over the pCMV-Rab-Rep plasmid alone (p = 
0.05 in a paired T-test). The results with the SCN10a Start TALEN pairs were less 
impressive. Neither the ELD/KKR, the 17aa expression vector, nor the original 
expression vector showed a significant increase compared to the pCMV-Scn10a-Rep 
plasmid background (17aa linker p = 0.1 in a paired T-Test, ELD/KKR and Long 
linker p > 0.5). 
 
This was a turning point for the project. It was obvious that the designed TALENs had 
poor cleavage efficiency in vivo. As the goal was to humanize the Scn10a gene, a new 
strategy needed to be designed: either re-design the TALENs, or switch to a different 
designer nuclease. During the last decade designer nucleases have made enormous 
strides, and a new emergent technology, CRISPR/Cas9 for genome engineering, had 
been successfully used in our lab. CRISPR/Cas9 design and gRNA assembly has the 
advantage of being less laborious than TALENs, and had been successfully used in 
our hands to modify mES cells. Therefore, a new experimental design was developed 
with CRISPR/Cas9.  
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Simultaneously, the question still about optimized construct design still remained. The 
large TC for SCN10A was not designed with nuclease assisted targeting in mind. It 
has long HA, flanked by FseI sites to linearize the construct (two requirements for 
traditional gene targeting). The question remained as to how designer nuclease 
assisted targeting in mammalian genomes effected vector design. Therefore, a new 
experiment was planned that could easily test different vector design parameters and 
their effect on targeting efficiency when using a designer nuclease.  
 
4.2 Improving targeting efficiency via targeting construct optimization: 
4.2.1 Hprt as a selectable locus to test targeting efficiency 
HPRT codes for the HGPRT protein; a transferase that has an important role in the 
purine salvage pathway.  It catalyzes the conversion of hypoxanthine to inosine 
monophosphate and guanine to guanosine monophosphate. While purines can be 
synthesized de novo by the cell, this expends energy. By utilizing the salvage 
pathway, the cell economizes energy expenditure. HPRT allows for both positive and 
negative selection by using medium supplemented with hypoxanthine, aminopterin 
and thymidine (HAT) which permits the growth of Hprt+ cells, but not Hprt- cells, 
while medium supplemented with 6 thioguanine (6-TG) kills cells that are Hprt+ and 
allows Hprt- cells to grow.(128) As Hprt is monoallelic in male cells (Hprt is located 
on the X chromosome) this is an ideal system to test the efficiency of targeting in cells 
in different experiments (figure 10). 
 
 
Figure 10: Design of a quantitative experiment utilizing Hprt Wt R1 cells were electroporated with 
Cas9 and gRNA expression plasmids that recognized Hprt exon 6. NHEJ was allowed to occur, and 
cells with a damaged Hprt were selected for with 6-TG. A new gRNA expression plasmid recognizing 
the mutation (and not wt) was designed. The mutated exon 6 was repaired via HDR with donor DNA.  
 
In order to knock out Hprt in R1 m ES cells, exon 6 of the wild type gene was 
damaged with Cas9. Exon 6 was selected as its structure is vital to the catalytic pocket 
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of HPRT.(129) Wt R1 cells were electroporated with Cas9 and gRNA expression 
plasmids that recognized exon 6 (gRNA HPRT 6-1). NHEJ was allowed to occur, and 
cells with a damaged Hprt were selected for with 6-TG (figure 10). Multiple colonies 
were expanded and the NHEJ mutation was identified via sequencing (figure 11A). 
Mostly deletions, but also some substitutions, and a single integration were observed. 
The PCR primers used to sequence this region were placed 500 bp apart, so very large 
mutations will not be identified using this method. Two clones (c15 and c18) were 
chosen for phenotypic verification. Indeed, these clones are resistant to 6-TG and 
susceptible to HAT (figure 11B). The wt R1 cells were used as a control, and are 
HAT resistant and 6-TG susceptible. E14tg2a cells were used as an additional control. 
E14tg2a cells are missing part of the Hprt promoter and exons 1 and 2, and are 
therefore susceptible to HAT and resistant to 6-TG. C18 was chosen for experiments, 
as the 4 bp mutation resembles a commonly desired mutation (i.e. deletion or 
exchange of an amino acid). A new gRNA expression plasmid recognizing the c18 
mutation was designed. This gRNA (gRNA C18) encompasses the 4 bp mutation 
from c18, and can no longer recognize and cleave wt DNA. 
 
Figure 11 Genotypic and Phenotypic verification of Hprt- Cell lines (A) The sequence of seven 
Hprt- clones that have CRISPR/Cas9 induced damage were sequenced. All seven clones had indels 
around the cut site of the Cas9 induced DSB. (B) Two clones (C15) and (C18) were chosen for 
phenotypic confirmation. These clones are 6-TG resistant and HAT sensitive, and can therefore be used 
in selectable rescue experiments for repair of the Hprt gene. 
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4.2.2 Effect of homology arm length on targeting efficiency with CRISPR/Cas9 
4.2.2.1 Introduction 
Homologous recombination is a routinely used technique in gene targeting, however, 
though this technique has been in use for several decades, it has a relatively low 
efficiency. Early works focused on understanding the mechanism of HR, and trying to 
increase its efficiency. One parameter that was clearly shown to improve efficiency 
was using long stretches of isogenic DNA in the targeting vectors.  
 
Thomas and Capecchi described an increase in targeting efficiency with increasing 
HA length.(104) This study only compared three HA totals (4 kb, 5.4 kb and 9.1 kb) 
that suggested a non-linear relationship between HA length and homologous 
recombination at the Hprt locus. The dependence of targeting efficiency on HA length 
was also noted at the  gene of hybridoma cells,(130) 2 different locations in the Hprt 
gene,(131) and the Chinese Hamster Aprt locus.(132) Hasty et al. examined this 
relationship further, using a variety of targeting vectors between 1.3 and 6.8 kb at the 
Hprt locus.(133) They, too, observed a relationship between homology arm length 
and targeting efficiency, along with several additional observations. They noted that 
total homology less than 1.7 kb was insufficient to generate targeted events, and an 
increase of homology to 1.9 kb increased targeting events 5x.  
 
Hasty et al.(133) also examined asymmetric constructs (constructs with HA of 
differing sizes) and noted that an arm with 472 bp was just as efficient as a 1.2 kb arm 
in forming a double crossover. This indicates that it is total homology that is limiting, 
rather than a single homology arm. These findings were also observed by Scheerer 
and Adair(132) at the Chinese Hamster Aprt locus; when using asymmetric homology 
arms, they noted that one arm less than 500 bp made less effective substrates for 
targeting than substrates with a similar total HA length. They noted no effect on 
targeting frequency when the short arm was at the 5’ or the 3’ end of the construct. 
However, several reports have indicated that when a single homology arm was 
reduced to below 1 kb, the recombination does not have the same level of 
fidelity.(131,133,134) 
 
RESULTS 
56 
 
The optimal amount of homology is also unclear. Adding homology longer than 6 kb 
did not increase targeting efficiency in Hprt,(133) though Deng et al. showed a strong 
dependence on homology that saturated at 14 kb, rather than 6 kb in Hprt.(131) 
Similarly, Lu et al. did not observe an increase in targeting efficiency with arms 
longer than 8 kb (up to 100 kb) at the -globin locus of ES cells.(135) The optimal 
amount of homology may depend on chromosomal landscape, isogenicity, or other, 
undefined parameters. 
 
The presence of additional 3 kb of nonhomologous DNA at the ends of targeting 
vectors does not effect targeting efficiency at the Hprt locus,(131) nor did ~2 kb non 
homologous DNA at the ends of targeting vectors effect targeting efficiency at the  
locus.(130) This knowledge led to the use of negative selection genes (such as HSV-
TK) to select against unintended integration events.(136) Additionally, the size of the 
insert seems to have no impact on targeting frequency, as inserts ranging from 8 bp to 
12 kb in the Hprt locus all had similar rates of targeting.(137) 
 
The use of designer nucleases has abolished the need for long homology arms for HR 
to occur.(5,6) Indeed, recent publications have evaluated the requirements of 
homology with designer nucleases. Byrne et al.(33) utilized varying arm lengths from 
94 bp to 5 kb, including asymmetric constructs. They determined that flanking 
homology arms up to 2 kb resulted in the optimal targeting efficiency, and additional 
homology up to 5 kb reduced gene targeting efficiency. However, the authors used a 
standard amount of DNA per construct (not equimolar amounts).  
 
This leaves several unanswered questions about the optimal length for HA when using 
nuclease assisted targeting. The selectable HPRT assay (section 4.2.1) provides an 
eloquent solution to quantifiably answer this question. 
4.2.3 Construction of targeting vectors with different homology arms 
In order to examine how homology requirements are impacted by designer nucleases, 
a series of repair vectors of DNA with varying homology arm length were cloned 
from the BAC RP23-13N1 using standard recombineering techniques.(86) The 
homology arms varied in length from 200 bp each side (i.e. 400  bp total homology) 
to 10 kb each side (ie 20 kb total homology) (figure 12). Additional constructs that 
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had a standard 1 kb arm and one arm with varying lengths were cloned. A PvuI and an 
AgeI site was integrated in all constructs between the backbone and the homology 
arms to allow linearization of the construct.  
 
Figure 12 Subcloning Repair Vectors A) A series of repair vectors with homology arm length 
varying from 200 bp to 10 kb on each side were subcloned from a BAC carrying the Hprt gene. Some 
constructs were symmetrical (same amount of homology on both sides) and some asymmetrical (one 
standard 1 kb arm and one arm of varying length).  
 
4.2.4 Targeting efficiency increases with total homology arm length 
In order to test the effect of homology arm length on Cas9 induced DSB repair, 
standard amounts of DNA were used in all experiments. Repair vector amounts 
equimolar to 10 μg of a 4 kb total homology repair vector were used. This amount 
was chosen, as when a titration with increasing concentration of repair vector was 
performed, at 10 μg, the system was not yet saturated (figure 13A). 
 
For plasmid electroporation experiments, a great excess of gRNA expression plasmid 
(15 μg) compared to Cas9 expression plasmid  (5 μg) was used to limit off target 
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effects that could be caused by excess Cas9 protein in cells.(65,72,73) Each 
electroporation was completed at least twice. 
 
 
Figure 13 Effect of homology arm length on targeting efficiency A) Titration of different 
concentrations of a 4 kb repair vector. At 10 μg of DNA/ 5x106 cells, the system is not saturated, and 
this amount was chosen for calculations of equimolar concentrations of the other repair constructs. B) 
Repair of Hprt- c15 cells with circular and linear repair constructs with varying HAs and a 100 bp 
single stranded oligo with gRNA and Cas9 expression plasmids. C) Repair of Hprt- c18 cells with 
circular and linear repair constructs with varying HAs with and without gRNA and Cas9 expression 
plasmids. D) Repair of Hprt- c18 cells with asymmetrical circular and linear repair constructs with one 
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standard 1 kb HA and one arm of varying length with and without gRNA and Cas9 expression 
plasmids. E) Repair of Hprt- c18 cells with circular and linear repair constructs with varying HA with 
and without RNP. F) Repair of Hprt- c18 cells with asymmetrical circular and linear repair constructs 
with one standard 1 kb HA and one arm of varying length with and without RNP. 
 
A set of experiments was completed to compare several parameters of vector design 
for nuclease assisted targeting. First, the series of subcloned wt DNA with varying 
HA lengths with and without gRNA and Cas9 expression vectors were electroporated 
into 5x106 c18 cells. After electroporation, the cells were plated on gelatinized 10 cm 
culture plates and after 24 hours, 1x HAT supplemented media as added to the plates 
to select for Hprt+ cells. After 10 days, the colonies were stained and counted.  
 
As a control, C18 cells were electroporated with gRNA and Cas9 expression vectors 
alone. This gives us the background number of colonies that are produced by NHEJ at 
the DSB in mutated exon 6 in C18 cells. An average of 61 colonies were obtained. 
Nine of these colonies were sequenced to identify the NHEJ events. In 8/9 colonies, 
the three deleted nucleotides were replaced with random nucleotides. In 1/9 colonies, 
there were more significant deletions that led to a Hprt+ phenotype.  
 
A steep increase in targeting efficiency with homology arms up to 2 kb in length was 
observed, with a more gradual increase up to 20 kb. This is in contrast to previous 
results that indicate homology arms more than 14 kb (without nuclease assisted 
targeting) do not increase targeting efficiency(131,133,135) and in contrast to reports 
that indicate that HA more than 2 kb (with nuclease assisted targeting) decrease 
targeting efficiency.(33) Additionally, targeting efficiency with and without the Cas9 
expression plasmid was evaluated, and found that targeting increased dramatically 
when Cas9 was expressed. A maximum of 350-fold difference was observed when 
Cas9 was used. Finally, the targeting efficiency of linear vectors and circular vectors 
was compared. There was a slight increase in targeting with supercoiled, circular 
donor vectors for HDR when a DSB was induced. There were no colonies obtained 
with circular vectors without Cas9, as targeting without a nuclease requires a linear 
construct. When using a nuclease, the linearization and purification step can be 
eliminated, which simplifies the targeting protocol.  
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In order to ensure that the results obtained in this experiment were not exclusive to 
this C18, the experiment was repeated with another clone. Clone 15 has a 15 bp 
deletion and a single bp substitution (figure 11A). It was derived at the same time as 
C18, and is also 6-TG resistant and HAT sensitive (figure 11B). A gRNA that 
recognizes the C15 genome, but not the WT genome, was cloned into the gRNA 
expression vector. In contrast to the C18 cells, when C15 was electroporated with its 
gRNA and Cas9 alone, no HPRT+ clones were made. This is likely because the 15 bp 
deletion is too large for the cell to repair and produce a functional HPRT protein. 
When the cells were electroporated with the gRNA and Cas9 plasmids along with 2 
μg of 100 bp single stranded oligo, an average of 4 colonies were obtained. This 
shows that while ssOR is useful for small mutagenesis (section 4.3), its utility is 
greatly reduced for experiments that require larger mutations. The overall efficiency 
of HPRT repair is less with C15 (compare 13B to 13C). This is likely partially due to 
differences in the gRNA efficiency (section 4.5.3 for further discussion), but may also 
be due to the size of the lesion. The small 4 bp mutation can be corrected by c-NHEJ, 
but the larger mutation of C15 precludes the use of c-NHEJ. There was also a slight 
shift in the curve, with a sharp increase in efficiency up to 4 kb HA length vs the 2 kb 
HA in C18, which is especially noticeable in linear constructs. However, these results 
confirm that longer HAs increase targeting efficiency, that circular constructs are 
more efficient than linear constructs, and that while 2 kb total homology is sufficient 
for targeting using CRISPR/Cas9, an increase in HA length to 4 kb would be optimal. 
 
Next, targeting efficiency of asymmetrical constructs that had one standard 1 kb arm 
and a second arm of varying length (figure 13 D) was determined. As previously, 
5x106 C18 cells were electroporated with equimolar amounts of the both circular and 
linear repair vectors, 15 μg of C18 gRNA expression vector and compared targeting 
efficiency with, and without, 5 μg of Cas9 expression vector. Each electroporation 
was completed at least twice, and the colony numbers were counted after the HPRT 
assay. Again, a large increase in targeting efficiency with CRISPR/Cas9 was 
observed. Also, a steep increase in targeting as total homology increased was again 
observed. The difference between linear and circular construct targeting efficiency 
was more apparent in this experiment, with supercoiled, circular donors having a 
higher targeting efficiency. Constructs with one homology arm shorter than 200 bp 
show a minimal increase in targeting above NHEJ background (figure 13D), even 
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though symmetrical constructs with the same total homology had an increase in 
targeting above background. Once the HA was increase to 500 bp, an average of 1097 
colonies for circular and 415 colonies for linear constructs was obtained. This 
indicates that that there is a requirement for each homology arm, and that it is 
somewhere between 200 and 500 bp. This observation is in accordance with results of 
targeting without a nuclease induced DSB.(132,133) Though colonies can be obtained 
with homology arms as short as 200 bp each side (figure 13C), targeting efficiency is 
markedly decreased. 
4.2.5 Use of ribonucleoprotein to induce DSB 
Cas9 protein can either be produced by the cell when an expression plasmid is 
transfected into the cell, or purified Cas9 protein can be combined with an in vitro 
transcribed gRNA to form a RNP complex that can be transfected into the cell. To 
determine the effect on targeting efficiency, the two different transfection methods: 
co-electroporation of the donor, Cas9, and gRNA expression plasmids, and co-
nucleofection of the preformed RNP and donor DNA, were compared. The use of an 
RNP has several advantages over gRNA and Cas9 plasmid expression vectors. Firstly, 
RNPs have the possibility of being “cloning-free” by using an in vitro transcribed 
gRNA and commercially available Cas9 protein. Secondly, there have been several 
reports of expression plasmid DNA integration at Cas9 induced DSB both on target 
and off target(134,138) when small homologies between the plasmid and the genome 
lead to insertion of expression vector plasmid DNA. Finally, utilizing the RNP 
delivers a complete package of gRNA and Cas9, and does not require the cell to 
synthesize these components, thus ensuring temporal coordination of the reagents. 
Compared to expression plasmids, RNP editing is very fast.(70) Indels are detectible 
very shortly after electroporation, and reaches a plateau after 24 hours. Cas9 is rapidly 
removed from the cells, and is mostly absent within 24 hours. In contrast, plasmids 
delivered by electroporation take longer to begin editing the genome, and persist up to 
72 hours in the cell.(139) Since on-target cleavage reaches its maximum while Cas9 
protein is still being expressed, the only remaining effect would be off target 
cleavages. Indeed, Cas9 RNP exhibits a lower level of off target mutagenesis.(139) 
 
The C18 gRNA that recognized the 4 nt mutation in Hprt- C18 cells was in vitro 
transcribed and Cas9 protein was purchased from MPI-CBG. The RNP was pre-
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formed at RT for 10 minutes, and the RNP was mixed with the donor vector in Lonza 
ES Cell nucleofection solution supplemented with S1 and electroporated into C18 
cells using a Lonza nucleofector. For this experiment, 2x106 C18 cells were used, 
which is 2.5x less cells than electroporations using the Biorad electroporator, because 
of the limitations of the nucleofector solution and cuvettes (as suggested by the 
manufacturer). The cells were plated immediately after electroporation onto 
gelatinized 10 cm plates, and after 24 hours medium supplemented with 1x HAT was 
added to the plates to select for cells with a repaired Hprt. Each nucleofection was 
repeated at least twice. 
 
An electroporation of the RNP without repair template to determine the number of 
background colonies repaired by NHEJ resulted in an average of 116 colonies (more 
than the 61 colonies from the plasmid electroporation control) indicating that even 
with 2.5x less cells, cleavage was more efficient with the RNP than the plasmid 
system. As this experiment utilized 2.5x less cells, our initial thought was to use 2.5x 
less DNA, however, this produced so many colonies it was difficult to count using the 
stained colony HPRT assay. Therefore, the concentration of repair vector DNA was 
decreased eight fold to obtain a countable number of colonies.  
 
The RNP was then co-electroporated with equimolar amounts of the series of repair 
vectors used in figure 13 C/D to test the effect of HA length on HDR when a DSB is 
caused by the RNP. As seen in figure 13 E/F, even with 2.5x less cells and 8x less 
repair vector, the RNP produced similar number of repaired colonies with up to 10 kb 
total homology. The largest, 20 kb total homology showed a decrease in targeting, 
which may be due to the tendency of nucleofections to break up large constructs.(140) 
The same tendency was seen with the larger asymmetrical constructs (figure 13F). It 
appears that constructs over ~15 kb have less targeting efficiency when nucleofection 
is used, and this decrease is more prominent with circular vectors.  This is in contrast 
to electroporation, which did not see a decrease in targeting efficiency after ~15 kb 
(figure 13 C-F) (though no sharp increase is observed, either). This experiment once 
again verifies that targeting efficiency of DSB repair induced by Cas9 RNP (figure 
13E) increases with homology arm length, that circular constructs are more efficient 
than linear constructs, and that there is a steep increase in targeting efficiency with 
homology arm length up 2 kb then a leveling off of efficiency increase. The 
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asymmetrical (figure 13F) constructs once again show that it is overall homology that 
has the biggest impact on repair efficiency, as long as there is one homology arm 
longer than ~500 bp. 
 
While HDR is an effective means for gene targeting, it has several pitfalls. Vector 
design and assembly is a laborious process. The requirement for long HA is 
diminished with nuclease assisted targeting, meaning HA can be added via PCR, or 
even come from commercially purchased oligos. Therefore, the next section of this 
work examines the efficiency of repairing DSB with commercially purchased 
oligonucleotides. 
 
4.3 ODN repair of DSB 
4.3.1 Introduction 
Modification of the genome with oligonucleotides is possible without nuclease 
induced DSBs with efficiencies up to 2 %,(141,142) which is attractive in gene 
therapy applications, as ODNs do not require multiple targeting steps like selection 
marker removal. Additionally, in contrast to most HDR donors, ssODNs can be 
commercially purchased, and require no vector assembly. However, the targeting 
efficiency of ssODNs is quite low, though it can be increased by slowing replication 
fork progression,(143) or by using phosphorothioate bonds to prevent nuclease 
degradation.(144,145) 
 
The main limitation of targeting with ssODNs is decreased survival of modified 
cells,(8,145,146) especially when using protected oligos.(7,145) Gene editing by 
ssODNs requires a large amount of molecules to be introduced into cells, and can 
cause a reduced proliferation phenotype (RPP).(147,148) The mechanism of RPP is 
still not clear, however stalled replication forks have been suggested as the main 
cause.(149,150) However, when ssODNs are used in conjunction with nuclease 
induced DSBs, the amount of ssODN molecules that need to be introduced into the 
cell are reduced,(148) thus opening the doors for ssODN repair as an attractive 
alternative to HDR.  
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Much work has gone into optimizing ODN donor design by examining the repair 
efficiency of single stranded vs double stranded ODNs, strand bias, length and 
symmetry around cut site. Earlier works had indicated that without nuclease induced 
DSBs, oligos must be single stranded in order to be incorporated,(7) however, with 
induced DSBs, dsODNs can be inserted, but at a lower frequency than 
ssODNs.(146,151,152)  
 
Several reports have indicated a strand bias when using ssODN 
repair,(7,8,149,152,153) yet others have not seen a strand bias.(151,152,154) Reasons 
for strand bias have been attributed to titration of the ssODN by the gRNA(153) and 
to the dynamics of Cas9 protein interaction with DNA (Cas9 asymmetrically releases 
Cas9 from the cleaved, PAM distal, non target strand first).(151) Richardson et al. 
optimized ssODN design by designing ssODNs that are complementary to the 
nontarget strand and overlap the Cas9 cut site with 36 bp on the PAM distal side and 
91bp on the PAM proximal side (151), and Liang et al. also observed an increase 
when using asymmetric oligos,(146) though they did not observe a strand bias and 
therefore suggested a mechanism based on 5’ resectioning. The “optimal” length (80-
90 bp) of donor ssODNs might agree with the later logic. In contrast to HDR donors 
in which longer is better, ssODN repair is hindered by longer ssODN donors.(8,146) 
This may be due resectioning of the cut template resulting in overhangs of ~30-40 
bp(155) that form more stable annealing with shorter ODNs, though other factors such 
as secondary structures may also be at play. 
 
The Hprt system introduced earlier in this work (section 4.2.1) can also be used to 
examine the use of ssODN repair with nuclease induced DSBs. Therefore, the next 
part of this work focuses on repair of the C18 Hprt- cells with ODNs. 
4.3.2 Targeting efficiency with ODN 
As constructs with as little as 200 bp HA (400 bp total homology) were still able to 
repair a 4 nt defect in Hprt, the repair efficiency of ssODNs was the next logical step. 
An equimolar amount (calculated according to the repair constructs in section 4.2.4) 
of a 50 bp ssODN, 100 bp ssODN, ds50  bp annealed ODNs, and ds100  bp annealed 
ODNs was electroporated with 15 μg C18 gRNA and 5 μg Cas9 expression vectors 
into 5x106 C18 Hprt- cells. After 24 hours, the medium was replaced with 1X HAT to 
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select for Hprt+ cells. After 10 days, the colonies were fixed, stained and counted. To 
determine if a strand bias occurs at this location, both a sense and antisense ssODN 
were commercially purchased. These oligos were annealed to form the dsODNs. 
When an equimolar amount of ODN was used, there were no colonies obtained above 
the background number of colonies from NHEJ, indicating that the reduced homology 
in ODNs up to 100 bp is not enough for efficient gene repair. Therefore, increasing 
amounts of ODN were electroporated into the C18 cells (figure 14A). Here a linear 
increase in repair efficiency with increasing amounts of DNA was observed. The 50nt 
ss and dsODN showed the least amount of repair. ds100nt ODN and ss100nt sense 
showed similar levels of repair and 100nt antisense oligo showed the highest level of 
repair, though this difference was not statistically significant at all data points on the 
plot (figure 14A).  
 
 
Figure 14 ODN Repair A) Repair of C18 Hprt- cells with 50nt ssODN, sense and antisense 100nt 
ssODN, ds50nt ODNs, and ds100nt ODNs. B) Repair of C18 Hprt- cells with sense and antisense 
asymmetric oligos. 
 
4.3.3 Effect of asymmetrical oligos on repair efficiency 
As others had noted an increase in repair efficiency when using asymmetric 
oligos,(146,151) it was interesting to see if this would also be the case in C18 cells. 
Asymmetrical ssODN with 36 bp on the PAM distal side and 91 bp on the PAM 
proximal side(151) were purchased and increasing concentrations were electroporated 
into 5x106 C18 cells with 15 μg C18 gRNA and 5 μg Cas9 expression plasmids. A 
linear increase in repair was observed with increasing amounts of ssODN. There was 
an increase in repair efficiency compared to symmetric ODNs (compare figure 14B to 
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14A). There was a slight difference between sense and antisense asymmetric ssODNs 
(figure 14B), though the sense symmetrical ODN repaired better whereas the 
antisense asymmetric oligo performed better. The increase in repair of sense vs 
antisense asymmetrical oligo is not significant at all data points in the plot, and may 
be due to experimental differences.  
 
There are several advantages to targeting with ODN- the largest being affordable, 
commercial availability of ODNs that do not require vector assembly. However, there 
are several pitfalls that make ODNs impractical for gene therapy. Though 
optimization of ODN design may decrease some of these problems, the large amount 
of ODN required and resulting RPP will require more problem solving before they are 
a commonly used solution for gene therapy. 
 
Additionally, ODNs can only correct small mutations. When 2 μg of 100 bp ssODN 
was used to correct the 4 bp mutation in C18 cells, and average of 244 colonies were 
obtained (figure 14A). However, when 2 μg of 100 bp ssODN were used to correct 
the 15 bp mutation in C15 cells, an average of 4 colonies were obtained (figure 13B). 
As HDR showed clear advantages over repair with short homologies, the next step 
was to examine the HDR donor requirements for more even complex targeting 
exercises.  
 
4.4 Effect of homology arm length on CRISPR/Cas9 mediated deletion of large 
stretches of DNA 
4.4.1 Insertion of a cassette via CRISPR/Cas9 mediated HDR 
While gene knock-outs can be achieved with a single amino acid change, some 
experiments might require more extensive deletions or substitutions of DNA. In order 
to observe the effect of nucleases on a large deletion of DNA, a PGK-neo-pA (1528 
bp) cassette was inserted into exon 6 of Hprt (figure 15A). The insertion of this 
cassette deleted 43 bp of Hprt to ensure a KO phenotype of Hprt. The same gRNA (6-
1) that was used to cleave exon 6 of WT R1 DNA (section 4.2.1) was used to increase 
targeting of the cassette. A circular PBR322-amp-HPRT-PGK-neo vector with 10 kb 
total homology, and 15 μg RNA 6-1 and 5 μg Cas9 expression plasmids were 
electroporated into 5x106 R1 cells. After 24 hours, G418 selection was applied to the 
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cells. After 7 days, 6-TG was applied to the cells for 4 days and clones were picked 
and expanded. 
 
Figure 15 Insertion of a PGK-neo cassette into the Hprt locus A) Design of the PGK-neo cassette 
inserted into exon 6 of Hprt B) Southern assay to confirm single integration of the circular PGK-neo 
cassette into R1 cells. An internal neo probe was used on NdeI digested genomic DNA, producing a 
single band at 6785 bp in targeted cells. 
 
Because the neomycin resistance gene has its own promoter, multiple or random 
integrations of the cassette into the genome were possible. A southern assay was 
performed with an internal neo probe to ensure single integration of the PGK-neo 
cassette. All clones contained a single integration of the cassette, with the anticipated 
band size (figure 15B).  
4.4.2 Phenotypic confirmation of Hprt KO 
From these clones, A1 was chosen for further experiments. The phenotype of clone 
A1 was confirmed to be G418 resistant, HAT sensitive and 6-TG resistant (figure 16). 
R1 was used as a wt control, and is G418 sensitive, 6-TG sensitive, and HAT 
resistant. The PGK-neo cassette is 1528 bp, and gRNAs were designed to target the 
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PGK (5’ end of the cassette) and the neo/ poly A (3’ end of the cassette). The 
phenotype of these cells confirms they are suitable for rescue experiments for repair 
of the Hprt gene.  
 
 
Figure 16 Phenotypic confirmation of HPRT-PGK-neo clones HPRT-PGK-neo A1 is G418 and 6-
TG resistant and HAT sensitive, and can therefore be used in rescue experiments for repair of the Hprt 
gene. 
 
4.4.3 Effect of gRNA position on deletion of a PGK neo cassette 
The Hprt-PGK-neo targeted cells allow examination of several interesting questions 
pertaining to deletion of larger sizes of DNA. While there was a steep increase in 
targeting efficiency with up to 2 kb arms in C18 cells (figure 13 C-F) this was not the 
case for C15 cells, which have a larger mutation (figure 13B). In C15 cells, there was 
a sharp increase up to 4 kb, which shows better efficiency with longer HAs. HPRT-
PGK-neo cells allow for quantification of the effect of HA length on deletion of a 1.5 
kb PGK-neo cassette. Additionally, the length of the cassette allows for examination 
of the utility of using multiple gRNAs vs a single gRNA (figure 15A).  
 
The efficiency of the gRNAs were tested with the 4 kb circular repair vector 
previously used (section 4.2.4), by electroporating 5x106 HPRT-PGK-neo A1 cells 
with 15 μg gRNA expression plasmid, 5 μg Cas9 expression plasmid and the 4 kb 
total homology repair vector. Each electroporation was repeated at least twice.  
 
When HPRT-PGK-neo cells were electroporated with the expression plasmids for the 
gRNA and Cas9 without any repair vector, there were no colonies obtained from the 
control (gRNA+ Cas9 alone) (figure 17A). For simple deletions, a strategy that uses 
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ligation of the DSBs formed by two gRNAs is possible (section 4.6), however in this 
experiment, when two gRNAs were used together to excise the PGK-neo cassette, no 
colonies were obtained, as the 43 bp that were deleted upon insertion of the cassette is 
too large to be repaired by the cell and form a functional HPRT protein.  
 
An average of 355 colonies were obtained with neo-gRNA-5 that recognizes the neo 
(3’) end of the cassette (figure 17A). Two gRNAs for the PGK (5’) end of the cassette 
were designed and tested, as Pgk-gRNA1 had significantly lower repair efficiencies 
(41 colonies). The second gRNA designed to recognize the 5’ of the cassette (Pgk-
gRNA 8) exhibited a much better cleavage efficiency and produced an average of 484 
colonies (figure 17A). The difference in gRNA cleavage efficiency has been 
previously observed, and may be the result of the different melting temperatures of 
the gRNA sequence, or the chromatin environment(8,33,59) though other unidentified 
factors are likely to also play.  
 
 
Figure 17 Deletion of a 1.5 kb stretch of DNA A. Test of single and double gRNA efficiency with a 4 
kb circular HDR vector B. Deletion of a 1.5 kb PGK-neo cassette by HDR using linear and circular 
repair constructs with varying HA lengths. 
 
 
Two gRNAs co-electroporated with the circular 4 kb repair vector to remove the 
PGK-neo cassette was not more efficient than using a single gRNA at either end of 
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the cassette (figure 17A). The efficiency of a single gRNA over two gRNAs has also 
previously been observed at two genes in human iPSCs. (33) 
4.4.4 Effect of homology arm length on deletion of a PGK-neo cassette 
As no increase in targeting efficiency was observed with two gRNAs, further 
experiments were completed using the range of repair vectors previously used (section 
4.2.3) and a single gRNA that recognized the poly A of the neo gene. A 100 bp oligo 
was not able to remove the cassette, even at high concentrations (2 μg). In fact, a high 
efficiency of cassette deletion was not observed until 10 kb total homology was used 
(figure 17B). This is in contrast to the 4 nt repair, which saw a steep increase up to 2 
kb total homology, which is even more severe than the shift to 4 kb observed with 
C15 cells (compare figure 17B to 13B). Additionally, there was an overall decrease in 
efficiency (comparing repaired colony number) between deletion of a 1.5 kb cassette 
and a 4 nt repair. While some of this difference may be due to the difference in gRNA 
efficiency, as a gRNA that efficiently cleaved genomic DNA was used, this decrease 
in targeting efficiency is likely due to the size of the deletion.  
 
Once again, an increase in targeting efficiency with longer homology arms was 
observed, and, there was a difference in the HDR efficiency of circular vs linear 
constructs. The circular constructs were much more efficient at removing the cassette 
and still showed a non-linear increase in efficiency as homology length increased. The 
linear constructs showed a more linear increase and a much lower overall efficiency 
compared to circular constructs.  
 
Our results have shown the utility of HDR for small repair (section 4.2) and larger 
deletions (section 4.4). Other common gene targeting experiments require insertion of 
large stretches of DNA. The DSB that are induced by designer nucleases offers two 
interesting opportunities for inserting DNA: both by HDR and NHEJ. The next 
section of this work examines the efficiency of DNA insertion via these two DNA 
repair pathways. 
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4.5 CRIPSR/Cas9 permits NHEJ mediated deletions and insertions 
4.5.1 Introduction 
Several experiments with ZFNs and TALENs utilized the overhangs produced by the 
FokI nuclease to repair DSB with foreign DNA. Orlando et al.(6) utilized double 
stranded oligonucleotides with overhangs that matched the overhang produced by a 
ZFN to integrate the oligo into the genome. This process utilizes the microhomology 
between the oligo and the overhang produced by the ZFN to insert the foreign DNA 
via NHEJ. While overhangs that were homologous exhibited a higher level of 
insertion efficiency, sequence that was flanked by non homologous overhangs was 
also inserted. Perfect ligation events occurred more often with protected oligos, 
though non protected oligos were also perfectly inserted, though less efficiently. In a 
follow-up paper, Cristea et al.(156) utilized both TALENs and ZFNs to insert larger 
(~3 kb) transgenes utilizing NHEJ capture. In this set of experiments, the authors used 
a transgene donor with the same TALEN or ZFN recognition sites as the genomic 
recognition sites. The authors postulated that concurrent transgene cleavage in vivo 
using the same nuclease that cuts the genomic target site would increase targeting 
efficiency by decreasing transgene degradation. Indeed, the transgene was inserted 
only when simultaneously cut by the nuclease. The insertions were almost never 
perfect (small indels at either the 5’ or 3’ junction, most likely caused by reformation 
of the cleavage site and sequential cleavage by the nuclease) and sometimes resulted 
in multiple integrations of the transgene, either at additional genomic locations or in 
tandem at the target site. When the authors pre-linearized the transgene, they noted 
less efficient targeting efficiency due to exonucleic degradation in the cell.  
 
In a similar set of experiments, Maresca et al.(157) also utilized ZFN and TALEN 
induced overhangs to integrate large stretches of DNA into the genome. Called 
ObLiGaRe, this method solves the problem of sequential recognition site 
reconstitution and recleavage by alternating the orientation of the recognition 
sequences, thus locking the ligation product in a palindrome of half recognition 
sequences. This method sometimes resulted in perfect ligation sequences, but also 
resulted in indels and multiple, sequential integrations of the transgene.   
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 Nakade et al.(158) reported a system called PITCh which utilized three gRNA 
sequences and two different target recognition sites on the donor vector to integrate 
the donor DNA. While this proved the possibility of perfect ligation products from 
Cas9 ligation, the system was unnecessarily complex.  
 
Bachu et al.(159) examined Knock in Blunt-end Ligation (KiBL) of ~5 kb in HEK 
293 and CHO K1 cells. They observed that circular constructs integrated better than 
linear, and that cell type had an impact on both KIBL efficiency (0.17% in HEK293 
cells and 0.45% in CHO cells, with selection), as well as the fidelity of KIBL 
(HEK293 cells showed indels in 32/32 sequenced ligation events while CHO KI 
showed perfect ligation in 4/4 clones at the HPRT locus and a mixture of perfect 
ligations and indels at another location in the genome).(159) 
 
Geisinger et al.(160) also observed that deletions from two gRNAs depends on the 
gRNA itself (different gRNAs have different frequencies), and the orientations of the 
PAMs, but concluded that the majority of deletions were precisely repaired at several 
loci in the genome and with varying deletion sizes. They then used KiBL with PCR 
amplicons (without homology arms) to replace the sequence between two gRNAs 
precisely in both an immortalized human cell line and JF10 hiPSCs. Their findings 
indicated that the blunt ends generated by Cas9 cleavage can be used to knock in PCR 
cassettes in a homology independent manner, though with less efficiency than HDR 
repair (up to 4 percent without selection and up to 22 % with selection). Precise 
cassette junction integration only occurred in JF10 cells, and rarely occurred in 
HEK293 cells (as seen by Bachu et al.(159)). 
 
Cas9 makes a blunt end DSBs that are substrates for error free repair by c-NHEJ, thus 
reconstituting the gRNA recognition site that can be re-cleaved by Cas9. This cycle of 
cleavage, repair, and re-cleavage is broken only when the exonuclease processing of 
c-NHEJ or alt-NHEJ prevent cleavage by the nuclease. The heterogenous nature of 
the indels that are generated, combined with the fact that not all indels produce knock-
out phenotypes, means that screening and confirmation is required for downstream 
applications.  
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One drawback of KiBL is the theoretical caveat that only 50% of integrations will 
have the desired orientation. The Hprt experimental design used in this work excludes 
this possibility, as the Hprt gene function must be restored by a correctly integrated 
cassette. However, a screening process must be designed to screen for this possibility 
if the integration event is not selectable. 
 
The rescue Hprt assay gives the perfect opportunity to test the efficiency of Cas9 
induced blunt end ligation for insertion of DNA and to compare this to the efficiency 
of insertion of DNA via HDR. 
 4.5.2 Precise deletion of 672 bp from the Hprt gene 
In this experiment 672 bp of genomic HPRT DNA in R1 cells, including exon 6, were 
deleted by electroporating two gRNA expression plasmids (Hprt 67 and Hprt 76) and 
a Cas9 expression plasmid into 5x106 R1 mESC and plating them on gelatinized 10 
cm dishes in a low density in ES medium. After seven days, the media was 
supplemented 6-TG selection to isolate Hprt- cells. The gRNAs, and therefore the 
NHEJ ligation product, are located within introns (figure 18). Several colonies were 
expanded and sequenced. 672 clones 6 and 10 were precisely repaired, with an exact 
672 bp deletion. These clones were 6-TG resistant and HAT sensitive, thus making 
them suitable for selectable Hprt experiments.  
4.5.3 Design of a KiBL vector to test precise NHEJ mediated DNA insertion 
A new gRNA that identified the junction of the repaired cells was designed. A repair 
construct that consisted of the deleted 672 bp flanked by the same gRNA as the 
junction of the 672 cells was made using subcloning. The gRNA was introduced via 
the recombineering oligos in either the same direction (SD) as the genomic gRNA 
recognition site or in the opposite direction (OD) as the genomic gRNA recognition 
site (figure 18). When the gRNAs are in the same direction, the gRNA recognition 
site will be reconstituted by perfect ligation, and can be continually cleaved and 
ligated until indels form and stop the gRNA recognition. When the gRNA site is in 
the opposite direction, the gRNA will cleave both the genomic DNA and the vector, 
but the ligation product between the vector and the genomic DNA will no longer be 
recognized by the gRNA. Additionally, a PvuI site was inserted between the gRNA 
and the 672 bp in the ligation vector. This allowed us to linearize the construct in 
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vitro and compare ligation of the 672 bp vs ligation of the in vivo linearized ligation 
vector. 
 
 
Figure 18. Design of an experiment to test ligation efficiency Two gRNAs (gRNA 67 and gRNA76) 
were designed that recognize sequence flanking exon 6. Expression plasmids for these two gRNAs and 
Cas9 were electroporated in R1 cells. NHEJ was allowed to occur and Hprt- cells were selected for 
with 6-TG. Perfect ligation (with no indels) occurred in two colonies. A new gRNA (67/76 gRNA 4) 
was designed that recognized the unique junction caused by NHEJ. This gRNA sequence was added to 
a repair vector that replaces the 672 deleted bp in the same direction (SD) and in the opposite direction 
(OD) as the gRNA site in the genome of 672 C6 and C10 cells. 
 
4.5.4 NHEJ mediated ligation precisely inserts DNA 
Following the previous protocols, 5x106 672 C10 and C6 cells were electroporated 
with 15 μg of the 67/76 gRNA 4 expression vector and 5 μg of the Cas9 expression 
vector. When C6 and C10 were electroporated with expression plasmids for the 
gRNA and Cas9 (with no donor template), there were no colonies obtained, as the 
672 (which removed all of exon 6) cannot be repaired by the cell without a template 
(figure 19A). Next, in vitro linearized vector and circular vectors SD and OD that 
would be linearized in vivo were electroporated into the cells along with expression 
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plasmids for Cas9 and the gRNA. The in vitro linearized vector integrated with a very 
low efficiency (average of 5 colonies) while the in vivo linearized vector integrated 
much more efficiently. OD versions of the construct were anticipated to have a higher 
ligation efficiency, as the SD gRNA would be reconstituted and re-cleaved, allowing 
for deletions or inversions of the intervening DNA. However, this was not the case, 
and the SD in vivo ligation construct had higher levels of ligation (figure 19 A). The 
efficiency of in vitro linearized integration is quite low, and though in vivo linearized 
ligation is much higher, it is still less efficient than HDR (Compare 19A to 13C-F). 
 
 
Figure 19. Ligation and insertion efficiency A) Insertion of 672 with in vivo and in vitro linearized 
repair constructs. The in vivo circularized vectors have the gRNA flanking the insert in both the same 
direction (SD) and opposite direction (OD) as the genomic gRNA recognition site. B) Repair of 672 
C10 cells with a series of HDR vectors (section 4.2.3) with varying HA length. 
 
4.5.5 Repair of 672 with HDR vector templates 
Another common gene editing exercise is insertion of DNA sequence. In order to 
evaluate the efficiency of insertion of a deleted stretch of 672 bp, the same HDR 
repair vectors with varying arm lengths (section 4.2.3) were used. 5x106 672 C10 
were electroporated with equimolar amounts of the HDR vectors, 15 μg Hprt 67/76 
gRNA 4 and 5 μg Cas9 expression vector. The cells were plated on gelatinized 10 cm 
culture dishes, and after 24 hours, the medium was supplemented with 1x HAT to 
select for Hprt+ cells. After 9 days the colonies were fixed, stained, and counted. 
There were no positive colonies for 400 bp circular repair construct, as the HA do not 
extend past the deleted section. There were an average of 5 colonies obtained for the 
linear 400 bp constructs. This comes from ligation of the linearized cassette, and 
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occurs with a partial deletion of the genomic region, as the deleted 672 bp is larger 
than the 400 bp HDR vector. 
 
All of the HDR vectors have a decreased overall HA length of 672 bp. As such, 
especially for the smaller HDR constructs, a lower level of gene repair was expected. 
Indeed, this was the case with a slight decrease in the number of corrected colonies 
compared to HDR of the 4 bp mutation in C18 cells (compare figure 19B to 13C). 
Once again, here there was in increase in targeting efficiency with HA length and 
circular vectors repaired more efficiently than linear. There was a sharp increase in 
efficiency up to 4 kb, with a more gradual increase after that. Even with the longer 
HA, there is a slight decrease in targeting efficiency compared to repair of a 4 bp 
mutation (compare figure 19B to 13C). However, insertion of a 672 bp section of 
DNA was more efficient that deletion of a 1.5 kb fragment of DNA (compare Figure 
19B to 17B).  
 
This work has so far clarified several requirements for optimization of HDR vectors 
for several different types of gene engineering exercises with designer nucleases. One 
additional factor that can be easily examined with the selectable Hprt experiment is 
the requirement for isogenic DNA. In the next section, the requirements for long 
stretches of isogenic DNA when using designer nucleases in HDR are examined.  
 
4.6 Effect of Engineered Mutations in Homology Arms on Targeting efficiency 
with CRISPR/Cas9 mediated HDR 
4.6.1 Introduction 
The use of isogenic DNA, or rather DNA that lacks significant mismatches greatly 
impacts targeting efficiency. Letsou and Liskay showed that gene conversion was 
sensitive to a single mismatch within 1 kb,(161) and others showed that the use of 
isogenic DNA increases targeting frequency 10-20 fold at the retinoblastoma 
locus(162) and 25 fold at the creatine kinase m gene.(163) At the Hprt locus, a 4-5x 
increase in targeting efficiency was found when using isogenic DNA,(131) though the 
number and location of the mismatches were not identified, this data indicates a 
requirement of a minimal stretch of DNA with perfect homology to the target locus. 
Reports using BACs as targeting constructs indicated that as homology arm length 
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increases, the requirement for isogenicity decreases,(164) and as repair of DSB 
requires less homology, determining the requirements for isogenicity when using 
CRISPR/Cas9 would be valuable for optimizing HA length.  
4.6.2 Differences between isogenic R1 DNA and RP23 BAC library at Hprt exon 
6 
For previous experiments (section 4.2.1), a 4 nt mutation in C18 Hprt- R1 cells were 
repaired with vectors that were subcloned from a commercially purchased BAC. The 
RP23-13N1 BAC was derived from pooled tissues from three C57BL/6J female mice. 
R1 cells, in which these experiments are performed, have a 129 genetic background. It 
was unclear if these two genetic backgrounds had identical sequences at the Hprt 
locus- and if there were mutations, if they effected targeting efficiency when using 
CRISPR/Cas9. In order to better study this, genomic DNA from R1 cells was 
extracted, digested with EcoRV, and used to subclone the 2 kb total homology vector. 
The sequence of the HA of the isogenic vector and the BAC vector were compared. A 
single C>G SNP was found, however, when the targeting efficiency of an equimolar 
amount of the isogenic construct was compared to the efficiency of the BAC derived 
vector with the same HAs, there was no significant difference in targeting efficiency 
found (figure 21A/B).  
 
4.6.3 Effect of engineered mutations in homology arms on targeting efficiency 
As a single SNP is quite small compared to the 2 kb HA, it was postulated that 
perhaps a larger mutation would have a greater effect. Mutations were engineered 
within the homology arms to determine the effect of non-isogenic DNA on targeting 
efficiency when using CRISPR/Cas9. In this experiment, silent mutations were first 
inserted into exon6 of Hprt using linear plus linear recombineering (section 3.34.8). 
These two mutations maintain the amino acid sequence of the gene while inserting a 
BssSI restriction endonuclease recognition site into the genome to allow for screening 
of the cells (figure 20). Then 5 bp were deleted from the 3’ homology arm where a 
single cutting BsmI restriction endonuclease site allowed easy deletion of 5 bp via 
linear plus linear recombination. This location was verified to lack a splice acceptor or 
branching location.  
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As before, 5x106 C18 cells were electroporated with 5 g Cas9 expression vector, 15 
μg C18 gRNA expression vector and the same molar amount as the 2 kb total HA 
constructs so the targeting efficiency could be compared. There was no decrease in 
targeting efficiency observed with the 5 bp deletion. The lack of decrease in targeting 
efficiency was surprising, but it was postulated that as the mutation was only 65 bp 
away from the 4 nt mutation in exon 6 (figure 20), the repair machinery treated the 
mutations as a single lesion. This led to the idea that mutations at different locations 
in the HA would have an increased/decreased effect on targeting efficiency, as it 
would decrease the length of homology that could be used during homology search. 
Therefore, a new design was established with engineered mutations along the 5’ 
homology arm that would put the lesions at varying distances from exon 6 (figure 20).  
 
Figure 20 Engineered mutations in a homology arm Two silent mutations were introduced into exon 
6 to make a BssSI restriction site. Single cutting restriction sites were identified in the homology arms 
of the 2 kb HDR construct. At each of these locations, either 5 bp were deleted, or a 6 bp NdeI site was 
inserted. This interrupts the homology at varying distances from exon 6. 
 
Four additional single cutting restriction endonuclease sites were identified along the 
5’ homology arm. Linear plus linear recombineering was used to either delete 5 bp or 
insert a 6 bp NdeI restriction endonuclease recognition site at each of these locations 
(figure 20). The 5 bp deletion or NdeI insertions were confirmed by restriction 
endonuclease digestion and sequencing of the vector. 5x106 C18 cells were 
electroporated with 5 g Cas9 expression vector, 15 μg C18 gRNA expression vector 
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and the same molar amount as the 2 kb total HA constructs so the targeting efficiency 
of vectors with engineered mutations could be evaluated. Surprisingly, no significant 
increase or decrease in targeting efficiency was observed with any of the mutations, 
no matter the location on the HA (figure 21). This indicates that the homology 
requirements for designer nuclease assisted repair are less than that provided in these 
constructs.  
 
Figure 21 Isogenicity does not impact targeting efficiency when using CRISPR/Cas9 Engineered 
lesions along the 3’ HA of a 2k total homology construct do not impact targeting efficiency, no matter 
their location on the homology arm. Neither a 6 bp insertion nor a 5 bp deletion have a significant 
impact. 
 
Summary 
The results so far of this work have established that while arms as short as 400 bp 
total HA are sufficient for HDR, for small mutations, there is an advantage to using 
longer HA, as HA up to 2 kb total homology drastically increase targeting efficiency. 
When larger, more complex exercises are required, even longer HA, up to 10 kb total 
homology drastically increase targeting efficiency. For both small and large exercises, 
increased homology beyond 4 kb provides further, smaller increases in targeting 
efficiency. Circular constructs perform better than linear constructs in all HR targeting 
exercises, and there is no need to clone isogenic DNA from the genome. With the 
optimized TC parameters in mind, humanization of the Scn10a gene was attempted 
again. 
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4.7 Humanization of the mouse Scn10a gene using CRISPR/Cas9 
4.7.1 Targeting strategy for the Scn10a gene 
Previous works have examined the use of two nuclease recognition sites to evaluate if 
dsDNA breaks at both ends of the gene replacement improved targeting 
efficiency.(33) In this experiment they replaced a 2.7 kb THY1 human gene with its 
mouse counterpart in iPCS without selection. When using two nuclease recognition 
sites, they observed gene excision and inversions in up to 20.5 % of the population, 
while single or double gene replacements occurred in only 2 % or 8 % of the 
population respectively. While the use of antibiotic screening can ensure targeting of 
one allele, the other allele must be screened for deletions. Additionally, depending on 
the design of the experiment, the cells must be screened for inversions. As the authors 
found that targeting with a single gRNA produced single gene replacements in up to 
15 % of the population, and double targeting in up to 11 % of the cell population, they 
recommended using a single gRNA targeting strategy.(33) However, several 
publications have shown that deletion frequency declines with increasing deletion 
size,(165-167) and Byrne et al.(33) noted that the efficiency of deletions relied more 
heavily on the efficiency of the specific gRNA pairs. Therefore, a strategy with two 
gRNAs that cleaved at the 5’ end and the 3’ end of mScn10a was utilized, as the 
gRNAs are 85 kb apart.  
4.7.2 Loss of allele screen for humanization of the mouse genome 
In order to quickly screen colonies for humanization of the Scn10a gene, a loss of 
allele (LOA) assay was utilized. qPCR primers were designed using the NCBI primer 
designer tool that amplified 70-100 bp of DNA from the mouse 5’ Scn10a gene body, 
the mouse 3’ gene body, the human 5’ SCN10A gene body or the human 3’ gene 
body. These primers were tested on genomic R1 DNA and genomic H7 DNA to 
ensure they were specific, both in band size and to the species they were designed for.  
 
The fold change of expression was calculated relative to a wild type control using the 
ΔΔCt method.(168) In this method, the cycle threshold (Ct) values need to be 
normalized against the average Ct of an internal control. However, a control that 
worked for both human and mouse DNA was first needed.  
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Bejerano et al.(169) published a list of 481 different DNA segments that are more 
than 200 bp that have 100 % homology between human, mouse, and rat DNA. These 
areas of ultrahomology provided an excellent location to design qPCR primers that 
gave not just similar sized products, but completely identical PCR products that could 
be used as an internal control for both human and mouse genomic DNA. From the list 
provided, any regions from the X chromosome (1N) were excluded and actively 
transcribed regions that had ~50 % GC content were focused on. From this list, 
several genomic regions identified in which specific qPCR primers within the 
ultrahomologous regions could be designed using the NCBI primer design tool. 
Sequences located within the HAT1 gene (copy number =2N) and the MRRF gene 
(copy number =2N) were chosen and qPCR primers were ordered for these regions. 
The primers were tested in triplicate with both H7 and R1 genomic DNA and the 
results were compared to a previously used internal control Nxt2 (34) (copy number 
=2N mouse). The primer pairs correctly recognized both mouse and human DNA and 
produced a single band. Using the ΔΔCt method, both HAT1 and MRRF primers 
identified 2N in R1 and H7 DNA. As expected, the Nxt2 primer pair only identified 
2N in R1 DNA, and did not produce a product for H7 DNA. 
4.7.3 Generation of humanized SCN10A mES cells 
The TC carrying the human SCN10A gene is very large (137,763 bp). As shown 
earlier (section 4.2.4), very large constructs break up upon electroporation. Therefore, 
the TC was lipofected, along with the gRNA expression vectors for the 5’ and 3’ ends 
of the mouse Scn10a gene and Cas9 expression vectors into feederless R1 cells. After 
24 hours, the medium was supplemented with BSD and three days later changed to 
HYG selection. Although several colonies were resistant to BSD and HYG, only one 
colony had a deleted mouse Scn10a. This clone (G2) however, also exhibited multiple 
integrations of the BAC throughout the genome (figure 22). This low efficiency can 
be explained by the low transfection efficiency of three different expression vectors 
and a TC into the same cell via lipofection.  
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Figure 22 LOA Assay for Humanized SCN10A colonies Allele counts for R1 cells transfected with 
the SCN10A humanization construct and expression vectors for gRNA and Cas9. Primer pairs were 
designed for qPCR that amplify either the mouse or human genomic region.  
 
As good results were previously obtained when electroporating R1-derived cells with 
multiple gRNA and Cas9 expression vectors (section 4.2), the protocol was modified. 
First, the SCN10A TC was prepared for lipofection, and applied to an empty 6 well 
culture dish. Next 1x106 feederless R1 cells were electroporated with 3 g of each 
gRNA expression vector and 1 g of Cas9 expression vector, using the standard 
electroporation protocol. After the standard 5 minute recovery, the cells were divided 
to 3 wells of the 6 well dish (~333.000 cells /well) that contained the TC treated with 
lipofectamine. After 24 hours, the medium was supplemented with BSD for 3 days, 
and then changed to medium supplemented with Hyg. After 10 days, colonies were 
picked, expanded and screened by qPCR for mScn10a deletion and hSCN10A 
insertion.  
 
This protocol proved more successful, with 6 colonies showing a deletion of the 
mScn10a. However, only one colony, A6, showed a deletion of the mScn10a gene and 
a single insertion of the hSCN10A gene. The rest of the colonies have multiple 
integrations, and sometimes partial integrations, of the TC. Partial integrations could 
come from TC that are broken from DNA extraction, or they could be a result of 
crossovers between the high levels of homology between the mouse and human gene. 
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This could be avoided by multiple targeting steps (as in section 4.5), but multiple 
targeting steps can reduce germline transmission. (29-31) 
 
Additionally, LOA allele screening in itself is not definitive test for correct gene 
targeting. These clones must be further screened for correct integration by FISH or 
southern analysis. However, this work shows that it is possible to complete very 
complex targeting exercises when using designer nucleases when using an optimized 
TC design. 
DISCUSSION 
84 
5 Discussion 
Designer nucleases are rapidly changing how gene targeting is approached. This has 
led to several questions about optimal target construct design when using designer 
nucleases. This work has helped to clarify the optimum targeting vector design for 
several different kinds of complex targeting exercises, and then utilized this optimal 
design to complete a very complex targeting exercise: humanization of the SCN10A 
gene in ES mouse cells. 
5.1 Two TALENs exhibited a low cleavage efficiency 
This work evaluated two different TALENs that recognized the Scn10a gene. These 
TALENs both exhibited undetectable levels of cleavage with the T7E1 assay (figure 
7). Attempts to increase cleavage efficiency by optimizing the linker and using 
obligate heterodimeric TALEN expression vectors did not appreciably raise cleavage 
efficiency of the Scn10a TALENs (section 4.1.1.6). There are several possible reasons 
that TALEN cleavage was inefficient. Firstly, it is possible that the TALENs in this 
work were confounded by chromosomal position or some other unknown factor. The 
variability of TALEN binding efficiency has been noted in several different works. 
(48-51) It is possible that designing and testing additional TALENs would solve the 
problem. 
 
However, the overall low efficiency of TALENs, especially in cultured ES cells has 
been noted in other works.(8) The low efficiency of TALENs in cultured cells may be 
due to the sensitivity of TALENs to cytosine methylation.(52,53) This sensitivity 
might be overcome by utilizing special TALEN assembly kits,(53) freshly extracted 
mESC,(170) or by injecting TALEN mRNA into blastocysts(127) (which have 
reduced methylation(171,172)). The relatively low efficiency of TALENs in cultured 
mESC, and their comparatively complex assembly led us to change strategies and 
utilize CRISPR/Cas9 to induce DSB. 
5.2 Optimization of construct design for designer nuclease-assisted targeting 
Nuclease assisted targeting to achieve complex genome engineering has several 
unresolved issues related to experimental design. DSB repair differs mechanistically 
from conventional targeting, as it is promoted by the ends of the linear DNA targeting 
construct. In order to clarify targeting vector requirements for nuclease assisted 
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targeting, an experiment was designed that could easily test different design 
parameters and their effect on targeting efficiency when using a designer nuclease. 
5.2.1 HPRT is a selectable assay for construct design with CRISPR/Cas9 
HPRT is a selectable assay using medium supplemented with HAT, which permits the 
growth of Hprt+ cells, but not Hprt- cells, and medium supplemented with 6-TG, 
which kills cells that are Hprt+ and allows Hprt- cells to grow.(128) As Hprt is located 
on the X chromosome, it is monoallelic in male R1 mES cells and can be used to test 
the efficiency of targeting with different targeting constructs. R1 cells can be weaned 
from feeders, and grown on gelatinized plates to form colonies that are easily visible 
to the human eye. They can be fixed and stained to make counting easier, and Hprt 
rescue makes an excellent quantifiable experiment. 
 
This work presented several systems in which Hprt was interrupted. First, cleavage by 
a single gRNA (section 4.2.1) resulted in a 4 bp mutation from NHEJ. This small 
deletion could be repaired by HDR and various ODNs. Hprt was also interrupted by 
two gRNAs, which deleted a 672 bp stretch of DNA. This deletion was repaired via 
HDR and blunt end ligation (section 4.5.4). Additionally, a PGK-neo cassette was 
inserted into Hprt and this cassette was subsequently removed via HDR (section 
4.4.4). These mutated Hprt alleles and their quantifiable repair via ODN, HDR, 
NHEJ, and ligation indicate the versatility of the HPRT assay. 
5.2.2 Longer HA increase targeting efficiency 
Homologous recombination is a routinely used technique in gene targeting, however, 
it has a relatively low efficiency. One parameter that was clearly shown to improve 
targeting efficiency was using long stretches of isogenic DNA in the targeting vectors. 
While longer arms are better, the dependence on homology seemed to saturate 
somewhere between 6 and 14 kb,(131,133,135) with the optimal amount of homology 
likely depending on chromosomal landscape, isogenicity, or other, undefined 
parameters. 
 
Recent advances in designer nuclease-assisted targeting have led to unanswered 
questions about the optimal length for HA to repair induced DSB. The selectable 
HPRT assay (section 4.2.1) provides a solution to quantifiably answer this question. 
In order to systematically study the effect of HA length on targeting efficiency, a 
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series of repair vectors with varying HA length were cloned from the RP23-13N1 
BAC. The homology arms varied in length from 200 bp each side (i.e. 400 bp total 
homology) to 10 kb each side (i.e. 20 kb total homology) (figure 12). Additional 
constructs that had a standard 1 kb arm and one arm with varying lengths were 
cloned. These repair vectors were transfected into the cell with and without expression 
plasmids for a gRNA and Cas9. In all cases, targeting increased dramatically when 
Cas9 was expressed. A maximum of 350-fold difference was observed when Cas9 
was used. 
 
When a small, 4 bp lesion in Hprt was repaired with the series of HDR vectors, a 
steep increase in targeting efficiency with homology arms up to 2 kb in length was 
observed, with a more gradual increase up to 20 kb (figure 13C). When a, larger, 15 
bp lesion was corrected with the repair vectors, there was also a slight shift in the 
curve, with the sharp increase in efficiency up to the 4 kb HA length vs the 2 kb HA 
in C18 cells, which is especially noticeable in linear constructs (compare figure 13C 
to 13B). The overall decrease in targeting efficiency in C15 cells compared to C18 
cells can be attributed to the efficiency of the gRNA and the size of the lesion. 
 
Overall, deletion of a stretch of 1.5 kb DNA was less efficient than repair of a 4 or 15 
bp mutation (section 4.5.5). High efficiency of cassette deletion was not observed 
until 10 kb total homology was used (figure 17B), which is much different than the 
repair of a 4 bp mutation, which had efficient targeting with 2 kb total homology 
(compare figure 17B to 15C). While some of the decrease in targeting efficiency may 
be due to differences in gRNA efficiency, the shift in the curve indicates that the 
decrease in targeting efficiency is likely due to the size of the deletion. While these 
results need to be repeated, perhaps with a different chromosomal location, these 
results indicate that deletions are much less efficient than small corrections or 
insertions. 
 
When a deleted 672 bp stretch of DNA was reinserted by the same series of repair 
vectors used in section 4.2.1, there is a decrease in targeting efficiency, likely due do 
the decreased overall HA length (from the deleted 672 bp) (compare figure 19B to 
13C). Once again, there is a shift in the curve, with an increase in targeting up to 4 kb, 
and a more gradual increase after that. Though insertion of 672 bp is less efficient 
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than correction of a 4 bp mutation, it is comparatively more efficient than deletion of 
a 1.5 kb fragment of DNA (compare Figure 19B to 17A). 
 
In none of these cases were longer homology arms found to have a negative effect on 
targeting efficiency. This indicates that while short arms can be used, there are 
benefits to having longer homology arms. This work has shown this to be especially 
true for different targeting exercises, with deletions requiring longer HAs, and 
insertions and correction of larger lesions exhibiting greater targeting efficiencies with 
4 kb total HA. Smaller lesions could be efficiently repaired with 2 kb total HA as 
previously reported.(33) Therefore, there is not a single “optimal” homology arm 
length when it comes to nuclease assisted HDR. The optimal length depends on the 
experiment, and there are no drawbacks to having longer HAs. 
 
Another potentially important observation is that all curves that measure the effect of 
homology arm length are bimodal (except for linear repair vectors for large deletions), 
showing a steep increase followed by further moderate increases with longer HA. This 
may be because stability of the synapse requires 1-2 kb homology on either side, and 
that longer targeting constructs increase the probability that targeting constructs will 
find their matching sequences in the genome. The idea that a minimal amount of 
homology is required for synapse stability is further supported by the results obtained 
from asymmetrical construct repair and repair constructs with engineered mutations, 
as targeting efficiency does not decrease when mutations are introduced to the 
homology arm (section 4.6). 
5.2.3 Minimal homology arm length 
Asymmetrical constructs with one homology arm shorter than 500 bp showed a 
minimal increase in targeting above NHEJ background (figure 13D). This observation 
is in accordance with results of targeting without a nuclease induced DSB.(132,133) 
Once the asymmetrical HA was increased to 500 bp, an average of 1097 colonies for 
circular and 415 colonies for linear constructs was obtained. Symmetrical constructs 
showed a similar pattern, with constructs that had 200 bp each side showing minimal 
increases over background NHEJ, and constructs with 500 bp each side (1kb total 
homology) showing a greater increase (figure 13D). Other works have identified that 
HA as small as 50-100 bp can repair a DSB caused by a nuclease, (5,6) and this work 
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has not identified a true “minimal” homology arm requirement. In fact, though 
equimolar amounts of a 50 bp dsODN did not repair the 4 bp mutation in C18 cells, 
when the concentration of dsODN was increased, even this short oligo with 25 bp 
homology each side of the mutation was able to repair Hprt (figure 14A). It is likely 
that the true minimal HA length for nuclease assisted targeting varies with 
chromosomal landscape, targeting exercise, and nuclease efficiency. Indeed, nuclease 
assisted targeting can even use microhomologies(6,156-158) or no 
homology(159,160) to ligate in pieces of DNA (section 4.5). What is clear, however, 
is that smaller homologies are not optimal for any of the targeting exercises examined 
in this work, with longer HA always being more efficient. 
5.2.4 HDR with circular vectors have higher efficiency than linear vectors 
In all experiments that compared HDR with circular and linear vectors (vectors 
linearized with RE before transfection into the cell) the circular constructs have a 
better targeting efficiency. This is especially true for the more complex targeting 
exercises (deletion of 1.5 kb and insertion of a stretch of DNA, but is also noticeable 
in the correction of the smaller, 4 bp mutations). This may be due to increased 
transfection efficiency of supercoiled, circular DNA. However, it may also be a result 
of degradation of the linear pieces of DNA by nucleases. The differences in the shapes 
of the curves when comparing circular and linear HDR constructs indicates nuclease 
degradation may be the cause (figures 13,17,19). 
5.2.5 ODN repair of DSB requires large amounts of DNA 
There are several advantages to gene repair with ODN- the largest being the 
affordable, commercial availability of customized ODNs. However, there are several 
pitfalls that make ODNs impractical for gene therapy. Though optimization of ODN 
design may decrease some of these problems, further optimization will be required 
before they are a commonly used solution for gene therapy. 
 
When an equimolar amount of ODN (calculated according to the HDR vectors in 
4.2.4) was used to repair the 4 bp mutation in C18 cells, there were no colonies 
obtained above the background number of colonies from NHEJ, indicating that the 
reduced homology of 50 to 100 bp is not enough for efficient gene repair. Increasing 
the concentrations of ODNs increased repair efficiency in all cases (figure 14). Even 
at a vast molar excess (i.e. 10 g of ODN), the efficiency achieved does not match the 
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targeting construct with 1 kb homology arms. Though a point of cell death caused by 
excess ODN was not reached with this titration, this would eventually occur, as excess 
ODN would eventually cause a toxic RPP.(147,148)  
 
There was no strand bias observed in this work. While there is evidence both for and 
against strand bias when using ODN to repair DSB, this work does not support strand 
bias related to the orientation of the ODN, and indicates that the ODN can be 
designed in either orientation with no impact on repair efficiency. 
 
As others had noted an increase in repair efficiency when using asymmetric 
oligos,(146,151) the efficiency of repair of a 4 bp mutation by both asymmetric and 
symmetric oligos was compared (figure A and B). There was an increase in targeting 
efficiency observed when asymmetric oligos were used. While the reason asymmetric 
oligos are more efficient at gene targeting is not completely clear, it may be due to 5’ 
resectioning,(146) gRNA titration of oligo, (153) or Cas9 release mechanisms.(151) 
As no strand bias was observed, the work supports a hypothesis of 5’ resectioning. 
 
This work did not screen for random, unintended ODN integration. ODN’s have been 
reported to clog replication forks and cause replication fork collapse (143) and double 
strand breaks. This work and others (6,156-160) show that exogenous DNA can be 
ligated into DSB. In fact, this principle is so well known that it is one of the methods 
of testing for off target effects.(173) When using ODNs to make small changes to 
DNA, a strategy should be identified that can check for off target integrations of the 
ODN. As higher concentrations of ODN are more likely to stall replication forks and 
have unintended integrations, it is important to use the smallest concentration of ODN 
possible. 
 
ODNs can only correct small mutations. When 2 μg of 100 bp ssODN was used to 
correct the 4 bp mutation in C18 cells, an average of 244 colonies were obtained 
(figure 14A). However, when 2 μg of 100 bp ssODN was used to correct the 15 bp 
mutation in C15 cells, an average of 4 colonies were obtained (section 4.2.4). An 
additional drawback of ODN repair is that it requires extensive screening for 
correction events. This is not the case for Hprt as this gene is selectable, but for other 
small mutations a screening strategy must be designed and many colonies must be 
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screened for correct integration while excluding off target integrations. Though ODNs 
have some advantages (easily commercially available), their usefulness in gene repair 
is somewhat diminished by the consequences of ODNs (only correct small mutations, 
off target integrations, and RPP). In many cases, an easily assembled HDR vector 
would be a more effective solution. 
5.2.6 RNP has advantages over expression vectors 
Cas9 protein can either be produced by the cell when an expression plasmid is 
transfected into the cell, or delivered to the cell as an RNP package. The use of an 
RNP has several advantages over gRNA and Cas9 plasmid expression vectors: RNPs 
can be “cloning-free,” they avoid the problem of expression plasmid DNA integration 
at Cas9 induced DSB,(134,138) RNP editing is very fast,(70) and RNP is quickly 
degraded by the cell which means that RNPs exhibit a lower level of off target 
mutagenesis.(139) In this work, the RNPs were more effective at HDR of DSB 
(section 4.2.5) than expression plasmids for gRNA and Cas9. The RNP required 8x 
less DNA (for 2.5x less cells) to achieve the same level of targeting compared to 
electroporation methods. This may be due to transfection efficiency of the RNP and 
repair vectors over the Cas9 and gRNA expression vectors and repair vectors. Less 
DNA however reduces the chances of off target integrations in the cell, making RNP 
delivery Cas9 an excellent method for inducing DSB. 
 
However, utilizing RNPs comes with several downsides. RNPs are most often 
transfected into cells via nucleofection. Nucleofections are known to break up large 
constructs,(140) which was also observed in this work (figure 13E). As seen earlier 
(section 5.2.2), different targeting exercises have different optimal homologies, with 
some exercises (like deletions) requiring larger total HA lengths. This means that co-
delivery of large HDR vectors and RNP is not optimal. RNPs can be lipofected into 
cells, however, the transfection efficiency is lower, and varies greatly between cell 
lines.(174) Additionally, the nucleofection kits for purchase (Lonza Mouse ES Cell 
Kit was used in this work), are expensive compared to standard electroporation. 
 
This means that for experiments there must be a cost/benefit analysis that will be 
different for each design. RNP cleavage to promote HDR that uses small HA would 
be beneficial, as it has less off target effects and requires less vector DNA. However, 
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larger HDR constructs that use larger HA would still require another mode of 
transfection (such as lipofection or electroporation) and therefore preclude the use of 
RNPs. 
5.2.7 gRNAs have different efficiencies 
The difference in gRNA cleavage efficiency has been previously observed, and may 
be the result of the different melting temperatures of the gRNA sequence, or the 
chromatin environment(8,33,59) though other unidentified factors likely also play a 
role. This work also observed a difference in gRNA efficiency (section 4.4.3), as two 
gRNAs in the same region had very different targeting efficiencies with a 4 kb HDR 
construct. This result suggests that it would be time saving to design and test several 
gRNAs simultaneously whenever possible, to increase the likelihood of choosing a 
gRNA with a good cleavage efficiency. 
5.2.8 Blunt end ligation is inefficient compared to HDR 
Several works have investigated the possibility of using NHEJ to ligate DNA into 
DSB.(6,156-160) As this work showed that with high concentrations of ODN, even 
50 bp total homology was sufficient to correct a 4 bp mutation (section 4.3.2), the 
next step was to evaluate the efficiency of integration of constructs with no homology. 
Therefore, a new experiment at the Hprt locus was designed. A stretch of DNA was 
deleted by CRISPR/Cas9 mediated DSB induced NHEJ. A new gRNA sequence was 
identified at the NHEJ junction. The deleted stretch of DNA was inserted into a vector 
flanked by the new gRNA recognition sites and PvuI sites. The PvuI sites permit in 
vitro linearization of the construct while the gRNA sites permit in vivo linearization 
when Cas9 and the gRNA expression vector are also expressed. 
 
The in vitro linearized vector integrated with a very low efficiency (average of 5 
colonies) while the in vivo linearized vector integrated much more efficiently. The co-
cutting of donor vector and target sequence has been noted before. (156,157) The 
gRNAs were inserted into the donor vector either in the same direction (SD) or 
opposite direction (OD) as the target vector. OD versions of the construct were 
anticipated to have a higher ligation efficiency, as the SD gRNA would be 
reconstituted and re-cleaved, allowing for deletions or inversions of the intervening 
DNA. However, this was not the case, and the SD in vivo ligation construct had 
higher levels of ligation (figure 19A). Though the gRNA sequences are recognized by 
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the same gRNA/Cas9 complex, the Cas9 binds to opposite strands of the DNA. 
Others have noted a strand bias in ODN repair due to the strand that Cas9 binds(154), 
and this may also be the case for blunt end ligation. 
 
When a series of HDR vectors with varying arm lengths was used to re-insert the 
excised DNA, the efficiency of insertion was much higher than in vivo linearized 
ligation (compare figure 19A to 19B). It was therefore concluded that HDR is a more 
efficient means of inserting DNA than blunt end ligation. 
5.2.9 Long stretches of isogenic DNA no longer necessary 
The use of isogenic DNA, or rather DNA that lacks significant mismatches greatly 
impacts targeting efficiency. Letsou and Liskay showed that gene conversion was 
sensitive to a single mismatch within 1 kb,(161) and others showed that the use of 
isogenic DNA increases targeting frequency up to 25 fold.(131,162,163) To determine 
the effect of mismatches within a homology arm on nuclease assisted targeting 
efficiency, an experiment was designed with engineered mutations along the 5’ 
homology arm that would put lesions at varying distances from Hprt exon 6 (figure 
20). Surprisingly, no significant increase or decrease in targeting efficiency was 
observed with any of the mutations, no matter the location on the HA (figure 21). 
 
Other works have identified that conversion tracts when a DSB is repaired is often 
less than 58 bp,(175) and in cases where the conversion tracts are longer, extensive 
end resectioning of the DSB has occurred. Further screening of the colonies obtained 
in this experiment can show if this work also finds such short conversion tracts. It is 
clear, however that along with reduced HA requirements, the requirement for perfect 
HA is also no longer necessary with nuclease induced DSB. 
5.2.10 Summary of optimization work 
This work has so far clarified several requirements for optimized HDR vectors for 
several different types of gene engineering exercises with designer nucleases. The 
results show that while arms as short as 400 bp total HA are sufficient for HDR, for 
small mutations, there is an advantage to using longer HA, as HA up to 2 kb total 
homology drastically increase targeting efficiency. When larger, more complex 
exercises are required, even longer HA, up to 10 kb total homology drastically 
increase targeting efficiency. For both insertions and small mutations, increased 
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homology beyond 4 kb provides further increases in targeting efficiency and for 
deletions homology greater than 10 kb total homology shows the best efficiency. 
Circular constructs perform better than linear constructs in all HR targeting exercises, 
and there is no need to clone DNA from the genome, DNA with minimal differences 
from a BAC library is sufficient. ODN repair and NHEJ ligation can incorporate 
DNA, but are significantly less efficient than HDR. 
5.3 Optimized targeting constructs make complex targeting exercises possible 
With the clarified requirements for HDR vectors, a very ambitious targeting exercise 
was attempted: humanization of the SCN10A gene. As circular vectors have higher 
targeting efficiency in all targeting exercise in this work, a circular construct was 
utilized. The construct was lipofected, and not nucleofected as nucleofection breaks 
up large constructs. The long HA as designed in the original construct were not 
reduced, as long HA improve targeting efficiency. The long HA made screening for 
targeting via southern assay difficult, so a LOA assay was designed to test for 
integration. In order to utilize the ΔΔCt method method(168)  (in which the fold 
change of expression is calculated relative to a wild type control), an internal control 
for both human and mouse needed to be designed to normalize the Ct values. From a 
list of ultrahomologous DNA segments,(169)  qPCR primers were designed that gave 
not just similar sized products, but completely identical PCR products that could be 
used as an internal control for both human and mouse genomic DNA. 
 
By electroporating the gRNA and Cas9 expression vectors into R1 cells, and plating 
them on lipofectamine treated TC DNA, one colony, was obtained that showed a 
deletion of the mScn10a gene and a single insertion of the hSCN10A gene. The rest of 
the colonies had multiple or partial integrations, of the TC. Partial integrations could 
come from fractured TC, or they could be a result of crossovers between the high 
levels of homology between the mouse and human gene. While these clones must be 
further screened for correct integration by FISH or southern (as LOA allele screening 
in itself is not definitive test for correct gene targeting), this work shows that it is 
possible to complete very complex nuclease assisted targeting exercises when using 
an optimized TC design. 
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6 Conclusions and Outlook 
Nuclease assisted targeting has drastically changed the outlook of gene therapy over 
the last decade. Designer nucleases have reduced the requirements for targeting 
vectors and have opened the doors for more complex targeting exercises such as 
simultaneous biallelic gene targeting or large regional replacements. Nuclease assisted 
targeting is mechanistically different from conventional targeting, and thus the 
requirements for targeted repair are different. The aim of this work was to clarify 
optimal construct design for designer nuclease assisted targeting and compare 
efficiency of HDR to repair with constructs that utilize little or no homology.  
 
While conventional targeting requires linear constructs with long homology arms 
containing long stretches of isogenic DNA, these requirements are all diminished 
when using designer nuclease assisted targeting. This work has compared homology 
arm requirements of several gene engineering exercises: correction of a small 
mutation, insertion of DNA, and deletion of DNA. The results show that circular 
constructs, with long HA have the best targeting efficiency. While repair via ligation 
and ODNs are possible, it is comparatively inefficient, and has the potential for off 
target integrations. 
 
Future work will focus on confirming off target integrations of ssODNs. While it is 
postulated that ODNs can be integrated off target at DSB or at junctions via SDSA, 
this is yet to be confirmed. This is a vital piece of the story, and will greatly impact 
the usefulness of ODN for gene therapy. More data points on the deletion curve will 
also clarify the curve shape. There is no current explanation as to why deletion of 
DNA with linear constructs is the only curve that is not bimodal. Repeating this 
experiment, perhaps at another locus will verify that this is not an experimental 
inaccuracy. Finally, sequencing of the repair events with engineered mutations will 
confirm that while longer arms stabilize the synapse, the actual gene conversion tract 
is much shorter. 
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